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Toll-like receptors (TLR) are germ-line encoded pattern recognition receptors (PRR) 
that detect infectious agents specific signatures present on pathogens collectively 
referred to as pathogen associated molecular pattern (PAMP). LPS, an endotoxin and 
poly(I:C) which is a synthetic oligonucleotide that mimics double-stranded RNA 
(dsRNA) binds to TLR-4 and 3 respectively and activates the TIR-containing adaptor 
inducing interferon- (TRIF)-dependent signal transduction cascade. Because 
Downstream of kinase (Dok)-1 and Dok2 were known to regulate TLR, we 
hypothesized that Dok3 may be involved in TLR regulation as well. We hence 
investigated if Dok3 is involved in TLR signalling in macrophages. 
 
In examining the role of Dok3 in TLR3 signalling, we showed that Dok3 
unexpectedly regulates TLR signalling positively. Dok3 is phosphorylated upon 
TLR3 and TLR4 stimulation. Dok3-deficient mice are more resistant to LPS- and 
poly(I:C)- induced septic shock and Dok3 is required for TNF, IL-12, and IL-6 
production by TLR3 stimulation in-vitro. In addition, IFN induction by TLR3 and 
TLR4, mediated through TRIF adaptor molecule, is significantly reduced by Dok3 
deficiency, owing to a defect in interferon regulatory factor (IRF)-3 activity and 
nuclear translocation. In particular, Dok3 is required for phosphorylation of upstream 
IRF3 kinase, AKT and TBK-1 by TLR3 signalling, and is required for induction of 
IRF3-dependent CXCL10 gene expression. Mechanistically, this is mediated through 
Dok3 direct interaction with TBK1 and TRAF-3 as determined by overexpression and 
confocal imaging studies in HEK293T cells. These data suggest a possible role of 




Poly(I:C) is known to activate RIG (retinoic acid-inducible gene 1)-I-Like Receptors 
(RLR) signalling in the cytosolic nucleic acid sensing pathway. We therefore further 
explored if Dok3 is also required for the RIG-I/MDA5 pathway by using transfected 
poly(I:C) as a ligand. We report here that indeed Dok3 is also required for RLR 
signalling as activation of IRF3 as well as production of IFNβ was defective in Dok3-
deficient cells upon RLR stimulation. Physiologically, we employed a viral infection 
assay and infected wildtype and Dok3-deficient macrophages with influenza virus and 
showed that IFNβ gene upregulation was impaired in Dok3-deficient cells and 
concomitantly, the virus replication was enhanced by Dok3 deletion.  
 
To investigate novel protein interacting partners of Dok3 in TLR4 signalling, we 
undertook a proteomic analysis approach. Mass spectrometry analysis identified one 
novel target of Dok3 binding, ABIN1 (A20-binding inhibitor of NFB) in RAW 
264.7 cells upon stimulation with LPS. The interaction of Dok3 and ABIN1 was then 
confirmed by immunoprecipitating Dok3 and immunoblotting for ABIN1 upon LPS 
stimulation. Further investigation delineated the signal transduction pathways that are 
effected downstream of Dok3 and ABIN1 in TLR signalling leading to a deleterious 
reduction in TNF production. These possible pathways include activation of A20, 
TPL-2 and p105 proteins. We showed here A20 protein expression is impaired in 
Dok3-deficient cells upon LPS stimulation whereas TPL-2 degradation is unaffected 
by loss of Dok3. These data suggested that Dok3 is required for A20 expression and 






Taken together, these data demonstrated the importance of Dok3‟s role in anti-viral 
immunity. Immuno-therapeutic applications for anti-viral studies in future may hence 
be aimed at fine-tuning the activity of Dok3 in vivo.  
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1.1 Human Immune System  
The immune system comprises two distinct arms: innate immunity and adaptive 
immunity. The innate immune system is conserved evolutionary and is an ancient 
response for host organisms to rapidly mount an immune response to foreign 
pathogens. This response involves cells of myeloid lineage such as macrophages, 
dendritic cells and neutrophils. The adaptive immune system however requires „pre-
education‟ of B and T lymphocytes with specific pathogenic components prior to 
eliciting highly specific immune responses (Hoffmann et al., 1999; Janeway, Jr. and 
Medzhitov, 2002). 
 
The recognition of pathogen associated molecular patterns (PAMP) by immune cells 
is mediated by various mechanisms. The host cell is equipped with an arsenal of 
receptors known as pattern recognition receptors (PRR) that can recognise PAMPs 
and evoke an immune response. These receptors include toll-like receptors (TLR), 
NOD-like receptors (NLR) and the retinoic-like receptors (RLR). More recently, 
newly discovered pathogen-sensing pathways include the intracellular nucleic-acid 
sensing pathways (Keating et al., 2011; Kumar et al., 2009).  
 
The engagement of the pathogen by innate immune receptors leads to an activation of 
a wide array of signal transduction pathways that are essential in the production of a 
range of cytokines and cellular events to eradicate the infection. Immune homeostasis 
is achieved by the balanced activation and shutting down of the signalling events in an 
orderly and timely manner that otherwise could lead to deleterious effects and result 
in immune disorders such as inflammatory diseases and autoimmunity (Parkin and 






Figure I-1 Principles in innate immune recognition by PRRs 
During microbial infection or breakdown of tolerance, accumulation of PAMPs, aberrant localization 
of foreign or self molecules or abnormal molecular complexes are recognized by PRRs. This event 
triggers PRR-mediated signalling and induction of an innate immune response, which ultimately results 
in clearance. However disregulation may cause inflammatory diseases or autoimmunity (Mogensen, 
2009). 
 
1.2 Pathogen recognition patterns: TLRs 
One class of PRRs comprise the Toll-like receptors (TLR). To date, there are about 11 
and 13 TLRs known in humans and mice, respectively. TLRs are type I integral 
transmembrane glycoproteins that consist of an extracellular domain, transmembrane 
domain and intracellular domain. The extracellular domain of different TLRs consists 




specificity. All TLRs share a common structural feature in their intracellular portions 
in the form of a Toll/IL-1 receptor (TIR) domain that is critical for signal transduction 
(Ferrao et al., 2012). Most TLRs (1, 2, 4, 5 and 6) are membrane-bound with the 
exception of TLRs 3, 7, 8 and 9 which are localised in the endosomes. Some TLRs 
function as a heterodimer, for example TLR1/TLR2 and TLR2/TLR6. All other TLRs 
function as homodimer (for example TLR3) or in conjunction with other receptors 
(for example TLR4 and CD14). Also, it was also demonstrated that CD14 which is 
expressed on the cell surface may enhance dsRNA-mediated TLR3 activation in 
myeloid DCs by binding to poly(I:C) directly and facilitating cellular uptake, 
internalization and trafficking to the endosome where TLR3 is localized or cooperates 
with TLR3 on the cell surface of human fibroblasts to internalize dsRNA (Lee et al., 
2006). In addition, it was recently demonstrated that MHC class II functions as a 
novel adaptor protein with Btk and CD40 at the endosome to further prime the TLR 
response, notably mediated by TLR3, 4 and 9 (Liu et al., 2011). These findings thus 
help to explain how TLR3 in particular can recognise a wide variety of substrates.  
The TLRs recognise different ligands, for example TLR1/TLR2 and TLR2/TLR6 
bind to triacylated and diacylated lipoproteins of bacterial and microbial origin 
respectively while TLR4 and TLR5 recognise LPS and flagellin of bacterial origin 
correspondingly. TLR3 detects double-stranded RNA from viral origins whilst 
TLR7/8 binds to viral component of single-stranded RNA.  TLR9 on the other hand 
recognises double stranded DNA viruses and methylated CpG motifs of bacterial 





Figure I-2 Recognition of PAMPs from different classes of microbial pathogens. 
Viruses, bacteria, fungi, and protozoa display several different PAMPs, some of which are shared 
between different classes of pathogens. Major PAMPs are nucleic acids, including DNA, dsRNA, 
ssRNA, and 5-triphosphate RNA, as well as surface glycoproteins (GP), lipoproteins (LP), and 
membrane components (peptidoglycans [PG], lipoteichoic acid [LTA], LPS, and GPI anchors). These 
PAMPs are recognized by different families of cell surface or endosomal PRRs such as TLRs 
(Mogensen, 2009)  
The binding of ligands by various TLRs result in the activation of TLR-induced signal 
transduction pathways. This is mediated primarily through the usage of two different 
adaptor proteins downstream of the receptors. These adaptors include the TIR-
receptor inducing to IFNβ (TRIF) and Myeloid-differentiation 88 (MyD88) which 
further recruits MyD88-like adaptors (MAL) and TRIF-related adaptors (TRAM) 
respectively (O'Neill and Bowie, 2007). All TLRs transduce signals via the MyD88 
dependent pathway except for TLR3 which signals exclusively through TRIF and 
TLR4 and thus is able to utilize both adaptors (Yamamoto et al., 2003). The TLR 
signalling pathways subsequently culminate in the activation of various transcription 
factors that are responsible for specific gene expressions by binding to promoters of 
gene encoding inflammatory mediators. This activation of the various transcription 
factors subsequently results in a co-ordinated event in an on-going immune response 




Some of these events such as cellular proliferation, migration and cytokine production 
are critical for overcoming infections (Sandor and Buc, 2005). 
1.2.1 Lipopolysaccharide  
Lipopolysaccharide (LPS) is commonly known to immunologists as an endotoxin 
(Raetz and Whitfield, 2002) and form a component of the outer membrane of Gram-
negative bacteria and can potentially elicit strong immune responses in various 
immune cell types such as dendritic cells, macrophages and B cells (Netea et al., 
2002). LPS is also commonly used by immunologists as a component in animal in-
vivo model study to examine septic shock. This model mimics the causative factors 
for the development of sepsis in potentially fatal human disease (Stewart et al., 2006). 
The innate immune receptor for recognising LPS was identified as TLR4. These 
critical discoveries were fundamentally impactful on the scope of modern medicine 
(Poltorak et al., 1998).  
1.2.2 Double-stranded RNA 
Double-stranded RNA (dsRNA) comprises two complementary strands and is the 
genetic material of some RNA viruses. dsRNA is also known as an intermediate 
product of some viruses during their replication cycles. One example is the dengue 
virus (Tsai et al., 2009). dsRNA from viruses can trigger type I interferon (IFN) 
response in vertebrates. Poly(I:C) is a synthetic analogue of dsRNA, a molecular 
pattern associated with viral infection. Both natural and synthetic dsRNAs are known 
to induce type I IFN and other proinflammatory cytokines production. dsRNA is 
primarily recognized by the pattern recognition receptor, TLR3, in the endosome and 
RIG-I/MDA5 in the cytoplasm for signal transduction in host cell anti-viral immune 




1.2.3 Toll-like receptor 4 
TLR4, also known as cluster of differentiation (CD) 284, is one of the toll-like 
receptors that is most extensively studied to date (Reeves and Wang, 2002). The 
receptor, its functional role and mode of activation on dendritic cells was discovered 
and deciphered by various research studies in different laboratories, with these 
research findings deemed as groundbreaking discoveries (Lemaitre et al., 1996; 
Poltorak et al., 1998; Steinman and Witmer, 1978). TLR4 recognises LPS, which is a 
component of the cell wall of Gram negative bacteria (Poltorak et al., 1998). 
Clinically, patients with severe toxins contamination from bacterial infection can 
develop sepsis that can be potentially fatal (Reading and Brecher, 2001). The LPS 
challenge is also commonly used as an in-vivo laboratory experimental protocol in 
mice to trigger endotoxin or septic shock (Copeland et al., 2005). As such, the 
identification of TLR4 as the main receptor for LPS presents answer for medical 
intervention.   
 
TLR4 has been shown to require a co-receptor CD14 (Kim et al., 2007), for 
signalling. Upon activation of TLR4 by its ligand, several signalling pathways are 
propagated downstream for specific gene expression (Rallabhandi et al., 2006). 
Signalling by TLR4 is unique as it is the only TLR present on the plasma membrane 
that utilises four different adaptor proteins to orchestrate specific signal transduction 
pathways. These adaptors include MyD88/MAL and TRIF/TRAM (O'Neill et al., 
2003). Following the assembly of adaptor proteins and kinases, the TLR4 pathway 
leads to the activation of two distinct responses. One of these pathways is required for 
the production of inflammatory cytokine production which is dependent on MyD88 




type 1 IFN which is mediated by TRIF-dependent signalling to TBK1 and IRF3 
(Fitzgerald et al., 2003b). 
1.2.4 Toll-like receptor 3 
TLR3, otherwise also known as cluster of differentiation (CD) 283, was identified in 
2001 as the receptor that binds dsRNA (Alexopoulou et al., 2001). There are multiple 
prerequisites as to how the receptor excludes its self-activation. Firstly, the structure 
of TLR3 showed that it resembles a solenoid horseshoe shape of which one side of it 
is masked by carbohydrate while the other side is glycosylation-free, presumably to 
prevent self-activation (Choe et al., 2005). Secondly, this receptor pre-exists as a 
dimer and activation is allowed only when its ligand, dsRNA cross-links TLR3 (de 
Bouteiller et al., 2005).  Last but not least, the receptor prevents pre-and/or self-
activation in order to mediate host self-to-foreign RNA recognition by its unique 
localisation in the endosome as opposed to other TLRs that are present on the plasma 
membrane (Schroder and Bowie, 2005). This is one way the TLR3 ensures that 
dsRNA will cross-link and activate a foreign invading source such as bacteria or 
viruses that have been subjected to cell-mediated phagocytosis or endocytosis and 
have trafficked to the endosome for TLR3-mediated antiviral immune response, 
similar to TLR9 activation (Latz et al., 2004). This finding was confirmed by studies 
whereby when chloroquine (a compound that disrupts endosome formation, hence 
disabling TLR3 proper assembly) was added to cells in culture, it resulted in a 
defective host innate antiviral response (de Bouteiller et al., 2005). 
 
Poly(I:C), which mimics dsRNA and binds TLR3 and activates the TRIF pathway 
TLR3 is activated by tyrosine phosphorylation at two distinct tyrosine residues, 759 




recently identified to be BTK (Lee et al., 2012). In both TLR3 and TLR4 signalling, 
TRIF can also interact with the TNF receptor-associated factor 3 (TRAF3) that 
subsequently activates downstream IKK-related kinases, TANK-binding kinase 1 
(TBK1) and inhibitor of kB kinase  (IKK). These IKK-related kinases then 
phosphorylates interferon response factor 3 (IRF3) and IRF7 which leads to IFN 
production, a cytokine important for an effective antiviral host immune response 
(Vercammen et al., 2008) (Figure I-3).   
 
When TLR3 is phosphorylated at tyrosine 759 residue, it leads to the recruitment of 
PI3K which in turn activates its downstream substrate AKT. This is termed the detour 
pathway or TRIF-independent signalling branch downstream of TLR3. More recently, 
studies have also demonstrated that AKT can activate TBK1 (Joung et al., 2011). In 
addition, this TRIF-independent signalling branch of TLR3 is also important for other 
cellular aspects of the host cell, including cell migration, proliferation and adhesion 
(Yamashita et al., 2012b). It is now well-characterised that upon tyrosine 
phosphorylation of TLR3, PI3K is recruited to the tyrosine 759 residue leading to a 
full activation of IRF3 via AKT, in addition to TRIF-mediated IRF3 activation 
(Hiscott, 2004).   
 
On the other hand, TRIF-dependent signalling pathway requires tyrosine 
phosphorylation of TLR3 at tyrosine 858 residue which recruits and mediates binding 
to BB loop of TRIF adaptor (Toshchakov et al., 2005). TRIF then allows the docking 
of RIP1 for subsequent NFB activation and TBK1 for IRF3 activation, two distinct 






c-SRC, a SRC-family kinase is also implicated in TLR3 signalling in antiviral 
immune response (Johnsen et al., 2006). Recently SRC and EGFR have been 
demonstrated to co-localise with TLR3 in the endosome and phosphorylate the two 
activation residues in TLR3. Furthermore abrogation of EGFR impaired TLR3-
mediated antiviral responses (Yamashita et al., 2012a). Thus it appears that TLR3 
signalling is more complex than originally thought and there may be more novel 
proteins awaiting discovery, adding on to the diversity of pathways downstream of 
TLR3. 
 
1.2.5 Critical signalling components of TLR pathway  
Adaptor proteins play a critical role immediately downstream of TLR signalling by 
coupling the receptor crosslinking to signalling cascades leading to the activation of 
transcription factors. In TLR signalling, five of these adaptor proteins have been 
identified. These include MyD88, MAL, TRIF, TRAM and SARM (O'Neill and 
Bowie, 2007). The commonality these proteins lies in the presence of the hallmark 
TIR domain that also serves as a conduit between the TLRs and the adaptor proteins 
themselves (Hultmark, 1994). All the adaptor proteins are known to positively 
regulate TLR signalling with the exception of SARM being known to function instead 
as a negative regulator (Peng et al., 2010). In addition, the RLR pathway in the 
cytosolic signalling pathway for antiviral immune response uses another adaptor 
protein, IPS-1 to signal IFNβ production (Kawai et al., 2005).  
 
We will discuss the adaptor protein TRIF in more detail as it is a crucial adaptor 




ubiquitously use MyD88 for signal transduction, TRIF is exclusively used by TLR3 
and TLR4 to mediate downstream signalling. TRIF is the largest protein among the 
other adaptor proteins in TLR signalling. It was identified by both database screening 
for TIR-domain containing proteins (Yamamoto et al., 2002) and in a yeast-2 hybrid 
screening with TLR3 as a bait (Oshiumi et al., 2003). The protein structure of TRIF is 
mainly divided into its N-terminal domain containing binding sites for TRAF6 and 
TBK1, an intermediary TIR domain for binding to TLR3 and a C-terminus containing 
a RIP1 binding site (Oshiumi et al., 2003). In TLR4 signalling, TRIF is known to 
mediate signalling with another adaptor protein, TRAM that functions as a scaffold 
(Rowe et al., 2006). TRIF-deficient mice were generated in 2003 and analyses of the 
mutant mice highlight its importance in activating IFNβ via the TBK1-IRF3 
signalling axis (Oshiumi et al., 2003; Yamamoto et al., 2003). This finding also 
resolved the long-standing enigma of the existence of a MyD88-independent 
signalling arm in innate TLR signal transduction pathways. More recently, TRIF was 
also identified to participate with DDX1, DDX21 and DHX36 to form a complex that 
senses dsRNA in DCs, further adding complexity and specificity to innate immune 
signalling in host antiviral defense (Zhang et al., 2011). 
 
1.2.2.1 TNF receptor-associated factor 3 
TNF receptor-associated factors (TRAFs) proteins are known to be evolutionarily 
conserved from Caenorhabditis elegans to mammals and they function as adaptor or 
scaffold proteins to recruit and assemble multiple proteins together to amplify 
downstream signals (Chung et al., 2002). There are about 7 known family members to 
date (Arch et al., 1998). The protein structure unambiguously include the C-terminal 




(Chung et al., 2002). Historically, most studies performed with TRAF proteins have 
focused on their roles in the TNF receptor superfamily with the exception of TRAF6  
(Bradley and Pober, 2001). TRAF6 was extensively studied in TLR4 signalling in 
disease conditions (Zhou et al., 2010). It is known to interact with IRAK, MyD88 and 
TRIF to signal to NFB downstream of the receptor (Bradley and Pober, 2001; Zhou 
et al., 2010). However, knockout studies with TRAF6-deficient mice revealed that 
IRF3 activation mediated via TRIF was relatively unaffected downstream of TLR3 
and suggested an alternative TRAF to be responsible for this signalling pathway 
instead (Hacker et al., 2006; Zhou et al., 2010). This promoted a surge in studies to 
identify the missing TRAFs in this pathway and led to the discovery of TRAF3 in 
antiviral responses. TRAF3 was identified previously as a protein that binds the CD40 
cytoplasmic tail and studies were focused on its role in adaptive immunity (Cheng et 
al., 1995). The studies pertaining to TRAF3 in TLR signalling have been increasing in 
recent years. A yeast-2-hybrid screening using TRAF3 as a bait pulled out TANK 
whereas a separate screen using TANK as a bait pulled out TBK1 (Chariot et al., 
2002; Pomerantz and Baltimore, 1999). Together, these findings suggest that TRAF3 
and TBK1 may have some interacting role. Indeed, TRAF3 and TBK1 were found to 
interact with TRIF in overexpression experiments in  HEK293T cell (Guo and Cheng, 
2007; Pomerantz and Baltimore, 1999). However, genetic ablation of TRAF3 was 
found to confer embryonic lethality and suggests that TRAF3 has a broader and 
indispensable role in organism development (Xu et al., 1996).  
 
Finally, studies with TRAF3
-/-
 MEFs revealed that TRAF3 has a specific function in 
signalling to TBK1-IRF3 for IFNβ production in TLR3 activation and is required for 




TRAF3 is activated remains unclear. We can at least hypothesise using TRAF6 
activation as an analogy and design experiments to prove the theory. TRAF3 may 
function similarly to TRAF6 as an E3 ligase  (Deng et al., 2000; Oganesyan et al., 
2006). E3 ligase catalyses both K48 and K63-linked ubiquitination, a form of protein 
post-translational modification, of which either leads to degradation of target protein 
via the proteasome or mediates activation by ubiquitin-mediated scaffold assembly of 
target proteins respectively (Chen, 2005). TRAF3 may self-polyubiquitinate upon 
activation and assembles proteins to activate TBK1 to phosphorylate IRF3, in a 
manner similar to TRAF6 assembly of TAB1 and TAB2 that subsequently activate 
TAK1 for NFB signalling (Kanayama et al., 2004). The mechanism of TRAF3 
activation in antiviral immunity therefore awaits further clarification. 
1.2.2.2 TANK-binding kinase 1  
TANK-binding kinase (TBK)-1 also known as NFB-activating kinase (NAK), shares 
a relatively high degree of homology with IKK and belongs to the IB kinase family 
that includes IKK, IKKβ and IKK or NEMO (Chau et al., 2008). However, TBK1 
and IKK functions deviate from the other IB kinases that were mainly implicated in 
activating NFB and as such are also termed as non-canonical IB kinase proteins. 
These kinases, especially TBK1 were predominantly required to activate the IRF3 
transcription factor for signalling to IFNβ (BURNETT and KENNEDY, 1954). 
TBK1, a serine/threonine kinase forms an integral large network of signalling proteins 
that are involved in TLR activating pathways including IRAKs, the IKKs and TAK1 





TBK1 was originally identified by yeast-2 hybrid screening using TANK as a bait 
(Guo and Cheng, 2007). TBK1 knockout mice displayed embryonic lethality at E14.5 
and suggests that this kinase is critically important for development (Hemmi et al., 
2004). Also, studies with TBK1
-/-
 MEFs underscore the importance of this kinase in 
directly activating IRF3 for IFNβ production in TLR3 and TLR4 signalling through 
the TRIF pathway (Hemmi et al., 2004). Last but not least, TBK1 is known to activate 
an antiviral immune state by forming several different complexes of which the 
constituting component depends on the type of cell and cellular stimuli. Some of these 
scaffolding molecules including FADD, TRADD, MAVS or SINTBAD have been 
identified to be recruited to the TBK1-containing-complexes (Chau et al., 2008). As 
such, it is possible that there are more novel proteins awaiting discovery, increasing 






Figure I-3 Regulation of IRFs and NFB via MyD88-dependent and MyD88-independent 
pathways by TLR pathways  
TLR4 uses MyD88-dependent and MyD88-independent pathways to activate NFB. NFB 
transcription factors are initially inactive and retained in the cytoplasm of cells by the IB subunits. 
Upon receptor activation, the IB subunits are phosphorylated and degraded, thus allowing the 
translocation of NFB p65/p50 subunits to the nucleus to effect proinflammatory gene transcription. In 
TLR4 signalling, the MyD88-independent pathway uses TRIF via adaptor TRAM to activate NFB in 
either a TRAF6-dependent manner or a TRAF6-independent mechanism. TLR3 however, interacts 
directly with TRIF to trigger these MyD88-independent pathways. TRIF also associates with TBK1 
and IKK, which in turn phosphorylate IRF3 and IRF7 respectively, leading to their nuclear 
translocation and induction of type I IFN genes. Upon activation, TLR3 also interacts with PI3K and 
activates AKT, leading to further phosphorylation and maximal activation of IRF3 (Sandor and Buc, 
2005). 
1.2.6 Positive and negative regulators of TLR signalling 
The study of TLR signalling has become increasingly complex with the surge 
in novel proteins being identified in recent years. In addition, proteins that are 
involved in TLR signalling usually display multifaceted roles and exhibit multi-
tasking abilities. The main bulk of proteins that are associated with TLR signalling are 
generally classified into positive and negative regulators based on their functions that 
are usually delineated by gene ablation studies in mice or by siRNA application in 
cells. However, one added tier of complexity is the fact that some of these well-
characterised proteins with defined positive or negative regulatory roles as 
demonstrated in previous studies are now challenged by more recent advanced 
technical studies to assume the opposite identity.  
We will describe some of these examples. MyD88 was long identified as the main 
adaptor protein in most TLR signalling. In MyD88 knockout mice, the inflammatory 
cytokine and IFNβ production were compromised in multiple TLR signalling 
(Muraille et al., 2003; Scanga et al., 2004). MyD88 mice were also more susceptible 




positive regulator (Muraille et al., 2003). More recently however, a separate study 
involving MyD88 appears to suggest that the adaptor protein functions as a negative 
regulator instead. The study showed that MyD88 negatively regulates TLR3-induced 
inflammation in human corneal epithelial cells (HCECs). This is possible by 
inhibiting the activation of JNK pathway (Johnson et al., 2008). Apart from this, 
another study also demonstrated that MyD88 negatively regulates the actions of TRIF 
adaptor, thereby inhibiting TLR3-induced IFNβ and CCL5 gene induction 
(Siednienko et al., 2011). One other study also clearly showed that MyD88 functions 
as a negative regulator to control hypergammaglobulinemia with the production of 
autoantibody in a bacterial infection (Woods et al., 2008). 
The other major adaptor TRIF, was also largely characterised as being a positive 
regulator in TLR signalling (Yamamoto et al., 2002; Yamamoto et al., 2003). This 
paradigm was challenged by a recent study that surprisingly demonstrated a negative 
role of TRIF in TLR-activated DCs. The authors found that the IL-12 production and 
co-stimulatory molecule expression by r-EA-as well as TLR4 and TLR9-treated DCs 
were significantly higher in TRIF-deficient mice and cells (Seregin et al., 2011).  
 
Other examples of a TLR-signalling associated protein that displayed dual regulatory 
functions depending on the context of receptor signalling and cell type studied include 
the PI3K, BTK and Lyn which are classified as protein kinases (Page et al., 2009). 
The PI3K was generally demonstrated as positive players in TLR signalling in many 
studies (Lindmo and Stenmark, 2006). However, it was also demonstrated to play an 
inhibitory role in other TLR-related studies (Fukao and Koyasu, 2003; Keck et al., 
2010). One particular landmark study showed that PI3K negatively regulates IL-12 




observed to have an enhanced T helper type 1 (Th1) in response to Leishmania major 
infection (Fukao and Koyasu, 2003). Last but not least, another interesting study 
demonstrated that Lyn, a SRC-family kinase, is a negative regulator of TLR4 
signalling in macrophages and the stimulated cells overproduce inflammatory 
cytokines including IL-6, TNF and anti-viral IFN/β as a result of the deficiency 
(Keck et al., 2010) whereas in many other studies Lyn is clearly  depicted as a 
positive regulator (Avila et al., 2012; Seo et al., 2001). 
1.3 Other Pathogen Recognition Receptors 
1.3.1 RIG-I-like Receptors  
RIG-I-like receptors (RLRs) are cytoplasmic sensors of viral RNA in host cell. There 
are three RLRs discovered to date. They are RIG-I (also known as DDX58), MDA5 
(also known as Helicard) and LGP2 (Martinon and Tschopp, 2005). The structure of 
RIG-I and MDA5 comprise a caspase recruitment domain (CARD) and a RNA 
helicase domain (RHD) (Yoneyama et al., 2005). The CARD is responsible for 
binding interacting partners in the signalling pathway to induce interferon production 
against viral infections and the RHD is important to bind viral nucleic acid (Saito et 
al., 2007). RIG-I can sense both viral RNA from virus infections and synthetic RNA 
that is transfected into the cytoplasm of the cell (Onoguchi et al., 2010).  
 
Activation of RIG-I leads to the production of type I interferon. These viruses include 
ssRNA viruses such as influenza viruses, vesicular stomatitis viruses (VSV) and 
paramyxoviruses. Genetic ablation studies using RIG-I-deficient mice underscore the 




mutant mice display a compromised innate immunity when infected with the RNA 
virus and resulted in increased susceptibility (Kato et al., 2006) (Figure I-4). 
 
Figure I-4 Intracellular RNA recognition and signalling.  
Cytosolic dsRNA or 5-triphosphate ssRNA is recognized primarily by the cytoplasmic RNA helicases 
RIG-I and MDA5, which mediate interaction with the adaptor IPS-1 is localized to mitochondria, and 
trigger signalling to NFB and IRF3 via IKK and TBK/IKKε, respectively (Takeda and Akira, 2005) 
 
There is an abundance of host-self RNA in the cell but this host-self RNA is different 
from foreign or viral RNA in that it does not activate RIG-I. This unique property of 
self versus foreign (non-self) RNA mediated activation of RIG-I is possible because 
of the presence of 5‟triphosphate (5‟PPP) cap or an attachment to the end of the RNA 
nucleic acid that allows discrimination from the host innate immune surveillance 
mechanism. During the maturation of nucleic acid in the host cell, the endogenous 
RNA will lose their 5‟PPP attachment by default and therefore is able to escape RIG-I 
detection. In contrast RNA from viral source contains 5‟PPP and is readily detected 




viral immune response (Schmidt et al., 2009). In spite of this, there are also short 
dsRNA usually less than 1kb that can also activate RIG-I in a 5‟PPP-independent 
manner (Kato et al., 2008). Some examples of these include short regions of reovirus, 
which is a dsRNA virus, and short poly(I:C) that have been found to activate RIG-I 
signalling (Kato et al., 2008). DNA virus infection can also activate RIG-I. This is 
because these viral DNA can be processed by RNA polymerase III in the cell to 
produce dsRNA and this is recognised by RIG-I (Ablasser et al., 2009). 
 
Binding to viral RNA by RIG-I is direct and occurs via recognition in the C-terminal 
domain (CTD) of the helicase. The crystal structure of RIG-I revealed that the CTD 
forms a cleft with positively charged amino acids that possibly interact with the 
dsRNA (Schmidt et al., 2010). The mechanism of how RIG-I specifically recognises 
the 5‟PPP moiety however remains elusive and is of intense interest to structural 
biologists. The binding of viral RNA to RIG-I subsequently results in a 
conformational change to RIG-I protein structure and expose the N-terminal CARD 
domain that allows protein interaction to occur. One immediate downstream 
interacting partner is the mitochondria-localised adaptor protein IFN-β promoter 
stimulator 1 (IPS-1) which possesses a CARD-like domain that can interact with the 
CARD domain of RIG-1.  The assembly of RIG-I and IPS-1 complexes trigger major 
activation of downstream signalling pathways such as NFB and IRFs for IFNβ 
production (Xu et al., 2005).  
 
The protein structure of IPS-1 comprises a CARD-like domain at the N-terminal and a 
transmembrane region at the C-terminal for localisation to mitochondria (Kawai et al., 




deficiency in mice or cells impairs host ability to mount an antiviral immune response 
to RNA viruses with defects in inflammatory cytokines production and production of 
type I IFN (Kumar et al., 2008; Miyake et al., 2009). However the role of IPS-1 
exhibits cell type specificity. In studies using pDCs, it was found that IPS-1 
deficiency did not affect its production of type I IFN in response to RNA virus. 
Therefore, it was suggested that TLRs constitute a more important antiviral defense 
arsenal as compared to RLR in pDCs. In other cell types like macrophages, 
conventional DCs and fibroblasts, both TLRs and RLRs are equally important in 
mediating antiviral response and are not mutually exclusive (Sun et al., 2006). 
 
Other proteins such as TRAF family proteins, more specifically TRAF3 and TRAF6, 
RIP-1 and caspases including caspase 8 and 10 and Fas-associated death domain 
(FADD) were demonstrated in various studies to be involved in RIG-I signalling for 
antiviral responses (Balachandran et al., 2007; Hacker et al., 2006; Takahashi et al., 
2006). However the exact mechanistic involvement of these proteins in the RIG-I 
pathway remains to be elucidated. 
 
Melanoma differentiation-associated protein 5 (MDA5) is structurally analogous to 
RIG-I as MDA5 also consists of RHD and CARD domains and is able to signal via 
IPS-1. However in contrast to RIG-I, MDA5 was demonstrated to recognise long 
forms of poly(I:C). More specifically, these long forms refer to length of more than 
1kb as a determinant for nucleic acid ligand requirement (Kato et al., 2008). Under 
the taxonomy classification of virus, positive sense single-stranded RNA virus, and in 
particular the Picornaviridae family, including the Enceplomyocarditis virus and 





Lastly, laboratory of genetics and physiology 2 (LGP2) is the third member of the 
RLR family proteins. Similar to RIG-I and MDA5, LGP2 contains RH domain but 
lacks an CARDs. Therefore LGP2 was initially referred to as a negative regulator of 
RLR signalling. However analysis of LGP2 deficient mice showed that these mice 
were susceptible to infection. Therefore LGP2 was reassigned as a positive regulator 
RLR signalling (Satoh et al., 2010). 
1.3.2 NOD-like Receptors 
The NOD-like receptors (NLR) belongs to another family of PRRs that are able to 
recognise PAMPs in the cytoplasm. These PAMPs are usually of microbial origins 
and include derivatives from Gram-positive and Gram-negative bacteria (Chen et al., 
2009). The NLRs mainly include NOD1 and NOD2 and they bind to specific ligands. 
These ligands include dipeptide g-D-glutamyl-meso-diaminopimelic acis (iE-DAP) 
and muramyl dipetide (MDP) (Chamaillard et al., 2003).  
 
The NODs proteins structure is mainly made up of three functional domains. First is a 
nucleotide-binding oligomerisation domain (NOD) that binds nucleoside triphosphate 
that forms critical component of pathogen nucleic acid that is required for nucleotide 
binding and self-oligomerisation. Next is a N-terminal effector binding region that 
consists of protein-protein interaction domains such as the caspase recruitment 
domain (CARD) domain, and finally a C-terminal leucine-rich repeats (LRR) to 
detect conserved microbial patterns and to modulate NLR activity (Inohara and 





At present, there are around 23 NLR genes in humans and 34 NLR genes in mice as 
predicted based on bioinformatics analysis (Harton et al., 2002). Structurally, the 
NLRs can be classified into three subfamilies also referred to as CARD-containing 
NODs, PYD-containing NALPs, or BIR-containing NAIPs based on the N-terminal 
domains whereas the LRRs in the C terminus of NLR proteins are thought to fold 
back onto the NOD domain, thereby inhibiting spontaneous oligomerisation and 
activation of the NLR protein (Duncan et al., 2007). It is thought that when NLRs 
engages ligands via the C-terminal LRR, it undergoes structural conformational 
changes such that it allows the oligomerisation via the NOD domain. As a result, the 
effector domains of the NLRs are now exposed and are able to induce the recruitment 
and subsequent activation of the CARD and PYD-containing signalling proteins due 
to close proximity and oligomerisation. These proteins include RIP2 that will trigger 
downstream signal transduction cascades (Kobayashi et al., 2002). 
 
The signalling pathways that are evoked when NOD binds its ligands include NFB 
and MAPKs that result in proinflammatory cytokine production (Franchi et al., 2009; 
Inohara and Nunez, 2003). A key serine-threonine enzyme that participates in NOD-
mediated signalling is RIP2, a member of the RIP family protein that also includes 
RIP1. This protein mediates interaction with NOD via the CARD domain and is 
mainly responsible for directly binding and promoting the K63-type polyubiquitlation 
of the regulator IKK and activation of the kinase TAK1, a prerequisite for the 
activation of the IKK complex. These events result in the degradation of the NFB 
inhibitor IB and the subsequent translocation of NFB to the nucleus, where 
transcription of NFB-dependent target genes occurs (Hall et al., 2008; Inohara and 




implications to human diseases mostly associated with inflammation. Polymorphisms 
in NOD1 are also associated with asthma and eczema (Hysi et al., 2005). On the other 
hand, there were three mutations (R702W, G908R and L1007insC) in amino acid 
residues found within the NOD2 LRR region that is responsible for the development 






 mice were generated to study the physiological roles of these 2 
proteins in vivo but the controversy generated in findings using NOD1 knockout mice 
further added more complexity rather than understanding. For example, in a study 
where NOD1
-/-
 primary fibroblasts were infected with Chlamydia trachomatis, the 
mutant cells produced lower proinflammatory cytokines as compared to wildtype 
control indicating that NOD1 can function as an antagonist against Chlamydia. 
Interestingly, when Chlamydia trachomatis was introduced vaginally into mutant 
mice, they were relatively unaffected and were able to clear the infection, suggesting 
redundancy of NOD1 and compensation by other NOD proteins or TLRs (Welter-
Stahl et al., 2006). Studies with NOD2
-/-
 mice were however more straightforward 
and direct and revealed that these proteins were critical in sensing intracellular 
pathogens like Listeria monocytogenes (Kobayashi et al., 2005). 
1.4 Transcription factor 
There are several transcription factors that play a critical role in the immune 
responses. Transcription factors are also known as sequence-specific DNA-binding 
factors that are proteins that binds to specific DNA sequences, thereby controlling the 
flow (or transcription) of genetic information from DNA to mRNA (Latchman, 1997). 
They can either function alone or in a complex with other proteins to either activate or 




a controlled transcription of inflammatory-related genes mainly mediated by a niche 
subset of transcription factors including NFB, AP-1 and IRFs (Sandor and Buc, 
2005). 
1.4.1 Nuclear Factor B  
The NFB transcription factor is responsible for many gene expressions in an immune 
response. It is made up of various subunits, the most common being p65 and p50 
subunit heterodimer. The p65/p50 heterodimer is usually held in an inactive state and 
prevented from activation by being bound to an inhibitor protein known as IB. 
Upon receptor engagement following a stimuli, it leads to the activation of the IKK 
complex containing NEMO (IKK), IKK and IKKβ, of which IKKβ then 
phosphorylates IB. A phosphorylated IB is then targeted for degradation 
following Ly48-ubiquitination in the proteasome. A released p65/p50 is then free to 
translocate to the nucleus to bind DNA on the consensus region and activate specific 
gene expression (Gilmore, 2006). 
1.4.2 Interferon Regulatory Factor 
The IRF family of transcription factors is largely responsible for mediating the 
production of interferon in an immune response. There are about 9 members of these 
family proteins that exist in both human and mice. The most recently identified 
member is IRF10 but its expression is found only in chicken and not human or mice 
(Honda and Taniguchi, 2006). These proteins played diverse regulatory roles in innate 
immunity, to prime the adaptive immunity and also to prevent tumor development 
(Honda et al., 2005b; Honda et al., 2006). For example, IRF1, 3 and 7 was found to 




receptor signalling. IRF1 was activated downstream of TLR9 in myeloid DCs to 
produce interferon- (Schmitz et al., 2007) whereas IRF3 and 7 was activated 
downstream of TLR3 and TLR4 in various cell types including B cells, macrophages 
and different subsets of DCs to induce interferon- production via TRIF (Doyle et al., 
2002; Honda et al., 2005a; Oganesyan et al., 2008). IRF5 was reported to be involved 
in macrophage polarization that subsequently determines a T cell immune response to 
Th1 or Th17 bias (Krausgruber et al., 2011). 
 
As transcription factors, these proteins are required to bind to specific regions of DNA 
to induce target gene expression. IRFs possesses DNA-binding domain (DBD) in their 
protein structure and are known to bind to the consensus DNA region known as the 
ISRE characterised by the presence of DNA repeats (consensus sequence: 
A/GNNGAAANNGAAACT) (Honda et al., 2006). Genetic studies using different IRF 
knockout-mice have revealed overlap and redundancy in the functions of the IRFs 
(Honda and Taniguchi, 2006). One example is studies with IRF3 and IRF7 knockout 
mice, which indicated that single knockout mice is still able to induce residual 
interferon- production upon activation while a double IRF3 and 7 knockout in mice 
showed complete ablation of IFNβ (Daffis et al., 2009). 
 
As thesis touches on IRF3, we will discuss this transcription factor in more detail. 
This particular transcription factor was identified by EST database search and is 
characterised because of its homology to IRF1 and IRF2 (Au et al., 1995). Its protein 
structure depicts a nuclear export signal, a DNA-binding domain and several 





IRF3 signalling leads to the activation of IFNβ, a type I IFN. The anti-viral cytokine 
is important for the eradication of viral infections. The transcription factor is normally 
inactive and predominantly resides in the cytoplasm. Upon appropriate activation 
signals, IRF3 is phosphorylated by its upstream direct kinase, TBK1 on serine 396 
residue and undergoes homodimerisation before translocating to the nucleus. Recent 
studies have also highlighted that IRF3 is not only activated by TLRs, but also by the 
intracellular RIG-1/MDA5 pathway that uses IPS-1 to induce IFNβ (Xu et al., 2005). 
In addition, new and novel DNA sensing pathways uncovered in recent innate 
immune studies have also demonstrated that the adaptor protein STING or MITA 
activates IFNβ production via TBK1 signalling to IRF3 (Ishikawa et al., 2009). 
IFNβ protein expression is translated from the gene transcription of the IFNβ 
enhanceosome (Kim et al., 2000). The IFNβ enhanceosome is mediated by co-
ordination of various transcription factors binding to different promoters and inducing 
the cytokine IFNβ. These 3 major transcription factors required for the activation of 
IFNβ are NFB, IRF3 and AP-1. The upstream activators of these transcription 
factors include MAPKs, TBK1 and IKKs (Honda et al., 2005b). 
1.5 Type I Interferon 
Interferons are specific cytokines that are released by activated innate cells when they 
are subjected to viral or bacterial invasion. The term „Interferon‟ was coined from 
“interfering with viral replication”. The family of interferons include type I IFN, type 
II IFN and type III IFN. Type I IFN include IFN, IFNβ and type II IFN include IFN 
whereas type III IFN include the IFN (Honda et al., 2005b). The members of type I 
and type II IFN mainly mediate anti-viral effects while IFN functions to prime the 




include the induction of myxovirus resistance gene Mx proteins and the 2‟-5‟ 
oligoadenylate synthetases (OAS) (Leroy et al., 2005). There are about 13 genes 
encoding for IFN but only one gene is responsible for encoding IFNβ (Honda et al., 
2006). 
 
IFNβ is induced via co-ordinated induction of specific transcription factors that lead 
to transcriptional activation of the IFNβ promoter. These transcription factors are 
NFB, IRFs, and AP-1 (Kim et al., 2000). The IFNβ enhanceosome region is made 
up of 4 positive regulatory domains (PRD I-IV) (Nourbakhsh et al., 1993). The 
upstream activators of NFB include the IKK, IKKβ and NEMO (Gilmore, 2006). 
The upstream activators of IRF3 and IRF7 involve TBK1 and IKK, respectively 
(Fitzgerald et al., 2003a) and the upstream activators of AP-1 involves the MAPKs 
(Ameyar et al., 2003).  
 
Type I IFN can amplify its own production through an autocrine feed-forward 
mechanism by binding to IFNAR1 and IFNAR2 receptor (Ihle et al., 1997). 
Signalling via the IFN receptor triggers the JAK-STAT pathway to enable further 
gene transcription (Ihle et al., 1997).This is mediated through the phosphorylation of 
the STATs proteins which is dissociated from the receptors, dimerise and translocate 
across the nucleus and associates with IRF9 to bind to the ISRE DNA region and 
activate the transcription of IFN-inducible genes (Schafer et al., 1998). 
 
Finally, there is emerging evidence to indicate the importance of type I IFN in 
modulating immune disease outcomes. Some of these diseases include viral and 




protective effects of type I IFN have been described in infections with Listeria, 
Mycobacteria, Brucella and Chlamydia (Trinchieri, 2010) as well as many influenza 
virus infections (Pauli et al., 2008). The increase in the levels of Type I IFN was also 
described in SLE and was found to be pathogenic (Banchereau and Pascual, 2006). In 
cancer, type I IFN have been demonstrated to be a potential therapeutic application 
and there were several studies that used type I IFN as treatments for various cancers 
including chronic myeloid leukemia and B cell lymphoma (Verma and Platanias, 
2002). 
1.6 Tumor necrosis factor  
TNF is a proinflammatory cytokine that is secreted by innate cell types such as 
macrophages and dendritic cells in an infection. It was first identified as a serum 
factor that was induced upon endotoxin challenge and was found to be able to lead 
some mouse specific tumors to necrosis in the in vivo model. This cytokine has now 
been demonstrated to play critical roles in chronic inflammation and infection and 
also to exhibit antitumor activities (Copeland et al., 2005). TNF  is expressed as a 
26-kDa protein.  It typically lacks a classic signal peptide. Newly translated TNF is 
normally translated and expressed on the plasma membrane of cells. It can be 
subsequently cleaved in its extracellular domain by the compound, matrix 
metalloproteinases into a soluble 17-kDa protein.  
TNF can activate TNF-mediated signal transduction pathway via binding to two 
receptors, namely type 1 TNF receptor (TNFR1) and type 2 TNF receptor 
(TNFR2). These two transmembrane receptors have many rich cysteine repeats in the 
extracellular N-terminal domains and share a high homology. In contrast however, 




receptors exhibited overlapping and distinct downstream pathways. The knockout 
mice of these two receptors have been generated and their phenotypes outcomes are 
relatively different. For example, when these two TNFR knockout mice were 
subjected to LPS sepsis model, the mice deficient in TNFR1 are resistant to lethality, 
whereas mice deficient in TNFR2 remain sensitive (MacEwan, 2002). 
1.7 Downstream of kinase 
The Dok family of adapters comprises seven family members, Dok1-7 (Cong et al., 
1999) (Figure I-5). Mutations in c-Abl was known to cause chronic myelogenous 
leukemia (CML), an aggressive form of lymphoid cancer or commonly known as 
cancer of the white blood cells (de Klein et al., 1982). This disease results from the 
uncontrolled expansion of myeloid lineage bone marrow cells including the 
macrophages, neutrophils and basophils. The diagnosis for this disease is usually 
performed by the detection of the Philadelphia chromosome (Ph) which is a 
chromosomal abnormality in patients. Ph was originally described in 1960s by Peter 
Nowell and David Hungerford at the University of Philadelphia (and hence the term 
Ph). This aberration in the chromosome results from a translocation where the 5‟ 
exons of the Bcr (breakpoint cluster) gene on chromosome 22 are fused to the c-Abl 
tyrosine kinase on chromosome 9 (de Klein et al., 1982). The subsequent by-product 
is a fusion or chimeric protein known as bcr-Abl and exists in either p185(Bcr-Abl) or 
p210(Bcr-Abl). In comparison to c-Abl which is inactive in its nascent state, Bcr-Abl 
is constitutively active by tyrosine phosphorylation and in turn continually turns on 
the cell-cycle related signalling cascade (Hantschel and Superti-Furga, 2004). On the 
other hand, the detrimental effects of Bcr-Abl also include its ability to suppress DNA 
repair thus contributing to genomic instability in host cells and chromosomal 




cells with viral-transducing methods and therefore a stable incorporation of Bcr-Abl 
results in malignant transformation of a variety of host cell lines including fibroblastic 
cell lines and hematopoietic cell lines (Konopka et al., 
1984).
  
Figure I-5 A phylogenetic tree demonstrating Dok family members.  
The phylogenetic tree was calculated using full-length sequences. Dok family members ranging from 1 
to 7 were classified accordingly into Type A, B and C subfamily (Favre et al., 2003). 
 
Dok1 was first identified as a novel protein with a molecular size of 62 kDa that may 
be associated with Bcr-Abl or c-Abl. p62 protein is found to be constitutively 
phosphorylated at the tyrosine residues and can be co-immunoprecipitated with p120 
rasGTPase-activating protein (GAP) from hematopoietic cells are isolated from CML 
patients (Carpino et al., 1997). The tyrosine phosphorylation of  p62 can also be 
detected when cell lines were stimulated with various ligands under different 
conditions including platelet-derived growth factor (PDGF), vascular-endothelial 
growth factor (VEGF),  colony-stimulatory factor-1 (CSF-1) and insulin growth factor 
(IGF) (Hosomi et al., 1994; Sanchez-Margalet et al., 1995). When B lymphocytes 
were cross-linked via BCR or via Fc receptors, a tyrosine phosphorylated p62 can 
also be detected (Yamanashi et al., 2000). Taken together, p62 was suggested to be 




phosphorylation and is a likely protein substrate for many of the tyrosine kinase in 
signal transduction.  
 
It was not until 1997 that this p62 protein was cloned by 2 different laboratories and 
identified and named as p62
dok 
or p62 Dok1 (Carpino et al., 1997; Yamanashi and 
Baltimore, 1997). Follow-up experiments revealed that Dok1 was phosphorylated by 
several tyrosine kinases including Tec, Lyn and SYK via HEK293T cells using 
overexpression systems (Yoshida et al., 2000). 
 
Further data analysis done in NCBI GenBank identified Dok1 to be highly conserved 
in many animal species, ranging from humans and primates to lower order species 
like zebra fish. Dok1 mRNA is estimated to be approximately 2kb by northern blot 
analysis and encodes for 481 amino acid residues (Carpino et al., 1997). Human and 
mouse Dok1 have a high overall sequence homology of approximately 83% 
(Yamanashi and Baltimore, 1997).  
 
The protein structure of Dok1 comprises an N-terminal Pleckstrin homology (PH) 
domain, intermediary phospho-tyrosine binding (PTB) domains and a C-terminal SH2 
target motif. The PH domain is responsible for membrane localization and the PTB 
domain is responsible for binding to phospho-tyrosine containing proteins. In addition 
to these unique protein domains, Dok1 also has as many as fifteen tyrosine residues of 
which most are located within the C-terminal SH2-target motif domain. It is notable 
that six of these residues contain the unique pYXXP sequence which is the 
preferential recognition sites of kinases including Abl and Crk (Songyang et al., 




comprising of PXXP motifs. This conserved motif is expressed commonly in SH3 
domain-containing proteins and hence suggests that Dok1 may function as an adaptor 
or scaffold protein to mediate protein-protein interaction via this conserved region. 
Indeed, an example that best describes this property of Dok1 is via an extrapolation of 
known interacting partners of insulin receptor substrate-1 (IRS-1) which has a protein 
structure highly homologous to Dok1 (Shi et al., 2004). IRS-1 binds to its receptor via 
its PH and PTB domain and subsequently undergoes tyrosine phosphorylation. Upon 
activation, its C-terminal region functions as docking sites for SH2-containing 
proteins. For example, these proteins include PI3K and SHP2 (Myers, Jr. et al., 1998; 
Yenush et al., 1998). This suggests Dok1 may function similarly to IRS-1 as an 
adaptor protein to orchestrate and propagate downstream signal transduction events. 
Dok1 was also the first of the Dok family proteins to be identified and subsequently 
more of the Dok family members were uncovered (Figure I-6). 
 
Figure I-6 Domain structure of Dok family protein shown with tyrosine phosphorylation sites 
indicated.  
Y denotes a tyrosine residue in the C-terminal region. Many of these tyrosines act as core residues in 
their respective SH2-binding motifs. PH, Pleckstrin homology domain; PTB, Phospho/tyrosine 




Dok2 was the second member of the Dok-family proteins to be discovered. It was 
cloned by three laboratories in 1998 (Di Cristofano et al., 1998; Jones and Dumont, 
1998; Nelms et al., 1998). It exists as a 56 kDa RasGAP binding phospho-binding 
protein isolated from a cell line that expresses p210
bcr-Abl
. In addition to uncovering 
Dok2 or p56
dok2
, an analysis of expressed sequence tag (EST) database helped 
uncover more of the Dok family proteins ranging from Dok1 to Dok6. Dok2 was also 
separately identified in two different yeast-two-hybrid screenings. Nelms et al used 
the interleukin-4 (IL-4) receptor motif as a bait and pulled down Dok2 which they 
named IL-4 receptor interacting protein whereas Dumont et al used the intracellular 
domain of the murine Tek receptor as a bait and pulled down Dok2 which they named 
Dok-related (Dok-R) (Jones and Dumont, 1998; Nelms et al., 1998). 
 
Dok2 mRNA is translated into a 412 amino acid Dok2 protein and there is no 
disparity between the homo sapiens and murine mRNA. The protein structure of 
Dok2 is similar to Dok1 and comprise the general PH and PTB and SH2 target motifs. 
It has however thirteen possible tyrosine residues of which six of them are of PXXP 
motifs. These two proteins exhibited an overall 34.8% similarity and expression of 
these two Dok family proteins is restricted to tissues of hematopoietic origins such as 
thymus, spleen and the lymph nodes. 
 
Dok1 and Dok2 have been speculated to mediate critical signal transduction events 
functioning as adaptor proteins. This is based on the fact that they are known to 
undergo tyrosine phosphorylation upon specific receptors stimulation. Dok1 and 
Dok2 are highly expressed in lymphoid cells including B and T cells, mast cells and 




as BCR, Fc receptor and TLRs are of immense interest. The generation of Dok1 and 
Dok2-single deficient mice or Dok1 and Dok2 double-deficient mice provided a 
model to critically study these proteins functions in a physiological setting.  
 
Single Dok1 and Dok2-knockout (KO) mice were generated in 2000 and 2004 (Niki 
et al., 2004; Yamanashi et al., 2000). The single deletion of Dok1 or Dok2 however 
did not affect the overall development of the organism and these mice were born at a 
normal Mendelian ratio. As Dok1 is highly expressed in B cells, studies were 
performed to elucidate its role in BCR signalling. Upon ligation of BCR with anti-
IgM, Dok1 was found to be phosphorylated in B cells. The phosphorylation of Dok1 
was much higher when B cells were stimulated with whole anti-IgG antibody, which 
co-ligate both the BCR and FcRIIB. Interestingly, proliferation of B cells upon BCR 
ligation proceeded normally in the absence of Dok1 deficiency compared with 
wildtype controls. Dok1 is however required for dampening ERK activation in BCR-
induced signal transduction and Dok1-deficient lymphocytes exhibited hyper-
phosphorylation of ERK2 in BCR signalling as compared to its wildtype counterparts 
(Yamanashi and Baltimore, 1997). This finding suggests a negative regulatory role of 
DOK1 in BCR signalling.  
 
Dok1 and Dok2 inhibitory roles were also evident in TLR signalling. Dok1 or Dok2 
single knockout mice were found to exhibit enhanced susceptibility to LPS induced 
sepsis (Shinohara et al., 2005). Combined deficiency in Dok1 and Dok2 however 
exacerbated the disease progression of the mice and they succumbed to death in less 
than a year due to the development of myelomonocytic leukemia (Yasuda et al., 




enlarged kidney. This occurred as a result of excessive expansion and infiltration of 
granulocytes and lymphocytes into the central periphery blood circulation. The 
mechanism behind the development of leukemia in Dok1 and Dok2 double-knockout 
mice was explained by the overly excessive responsiveness of the myeloid cells upon 
treatment with cytokines such as stem cell factor (SCF). In addition, these cells could 
not undergo normal apoptosis,  further aiding cancer progression (Yasuda et al., 
2004). As such, Dok1 and Dok2 exhibited a negative regulatory role in overall 
immune homeostasis and is required to suppress the development of leukemia. 
 
Dok1 and Dok2 were also involved in T cell functions. This is based on a study where 
Dok1 and Dok2 double-deficient mice were analyzed for their role in thymocytes 
development (Yasuda et al., 2007). Consistent with the negative regulatory roles of 
Dok1 and Dok2 in other receptor signalling, these proteins also demonstrated 
inhibitory functions in T cells. When the mice were immunized with antigens and 
examined for T-dependent (TD) responses, they exhibited a negative regulatory role. 
For example in vitro assays using CD4
+
 T cells from the Dok1 and Dok2 single 
knockout mice showed that these cells have increased proliferative response in culture 
and a higher production of IL-2 cytokine and these effects were synergistically further 
enhanced in the double knockout (DKO) mice and cells.  In the context of TCR-
mediated signalling, Dok1 and Dok2 were also demonstrated to be essential players. 
Dok1 and Dok2 are required to negatively regulate signal transduction pathways 
downstream of the TCR. In the absence of Dok1 and Dok2, T cells activated by TCR 
crosslinking displayed increased phosphorylation of T lymphocytes adaptor protein 
including ZAP70 and LAT as well as MAPKs such as ERK. Mechanistically, Dok1 




signalling through their PTB protein domain and so prevented a continual positive 
signalling in TCR activation. More interestingly, Dok1 and Dok2 double knockout 
mice developed autoimmune disease over time, characterized by the presence of high 
levels of autoantibodies to dsDNA and presence of immune complexes deposits in 
kidneys (Yasuda et al., 2007). These research findings suggested that Dok proteins 
may be attractive targets for therapeutic intervention in autoimmunity.  
 
Several other studies have highlighted the roles of Dok1 and Dok2 in more diversified 
receptors signalling, indicating such signalling is not limited to only receptors from 
cells of hematopoietic origins. There is increasing literature covering these areas and 
some of the conclusions suggest controversy to the current known knowledge of the 
Dok1 and Dok2 established roles. For example, Dok1 and Dok2 were demonstrated in 
one study to be important for osteoclasts formation and in its absence, osteopenia 
formed as a result (Kawamata et al., 2011). In a separate study, Dok1 and Dok2 were 
showed to be differentially regulated in platelets activation in response to thrombin 
and the authors raised an interesting possibility that Dok2 may play an important role 
in integrin outside-in signalling through a physical and functional interaction with 
integrin αIIb3. It is interesting to note that in this context scenario, Dok1 and Dok2 do 
not play a cooperative role but differential roles instead. Another study also 
demonstrated that Dok1 and Dok2 play opposing roles. In this study, the authors 
investigated the role of Dok1 and Dok2 in CD200 receptors which negatively regulate 
myeloid cells upon binding to its ligand CD200. They showed that when CD200R is 
activated, Dok2 phosphorylation preceded that of Dok1 and recruited individual 
specific subsets of signalling proteins downstream of the receptor and exhibited 




that Dok1 and Dok2, despite having high homology in protein structure, could display 
opposing effects in certain receptor systems. The conclusions redefined some of the 
current paradigms that suggest that the two proteins act in a cooperative manner most 
of the time. 
1.7.1 Downstream of kinase-3 
Dok3 was identified by two independent groups in 1999 and 2000 and was named 
Dok-L (Cong et al., 1999; Lemay et al., 2000). It is the third member of the Dok 
family of adaptor proteins. Dok3 expression is restricted to B cells and cells of the 
myeloid lineage including macrophages and dendritic cells. Both research groups 
utilised yeast-two-hybrid to fish out Dok3. The first group made use of the knowledge 
that Dok proteins have preferential binding sites for Abl and hence by using Abl as a 
bait, Dok3 was pulled down and sequenced (Cong et al., 1999). The other group used 
Csk instead as a bait together with SRC kinase and pulled down a novel adaptor that 
when sequenced, was found to be Dok3 (Lemay et al., 2000). Dok3, like the earlier 
discovered Dok1 and Dok2, comprises of a common protein domain structure 
including the amino terminal PH and PTB structures and the C terminal region of 
SH2-target motif with around four potential tyrosine phosphorylation residue sites. 
Interestingly Dok1, Dok2 and Dok3 share a high degree of similarity in their PH and 
PTB domains but not in the carboxyl terminal region. The most notable difference of 
Dok3 from Dok1 and Dok2 was the absence of the repeated YXXP motifs that enable 
Dok1 and Dok2 to interact with rasGAP. 
 
Similar to Dok1 and Dok2, Dok3 expression is limited to immune organs. It is 
expressed most abundantly in lymphoid organs such as the spleen and bone marrow 




role in T lymphocytes development and function. In comparative expression studies 
of the overlapping roles of Dok1, Dok2 and Dok3 using sorted primary cells, Dok1 
and Dok3 were discovered to be exclusively expressed during B cell developmental 
stages and in peripheral circulating B cells whereas Dok1 and Dok2 messenger levels 
were found to be upregulated in developing thymocytes. Therefore it is currently 
accepted that Dok1 and Dok2 function mainly in T cells whereas Dok1 and Dok3 are 
more important for B cells (Yasuda et al., 2007).  
 
In yeast-two hybrid studies performed by Cong et al, it was found that Dok1 and 
Dok3 interact with Abl via their PTB domains and this interaction is dependent on 
Abl kinase activity (Cong et al., 1999). Upon cross-linking of the BCR, Dok3 readily 
undergoes tyrosine phosphorylation and interacts with SHIP1 and Csk (Lemay et al., 
2000). Biochemical assays to decipher the effect of Dok3 in B cell activation were 
performed by overexpressing Dok3 in A20 B cell line and it was shown that Dok3 
played a negative role as BCR-induced IL-2 production was inhibited when there was 
increased levels of Dok3 in A20 (Robson et al., 2004). Site-directed mutagenesis 
studies were performed on Dok3 to investigate if tyrosine phosphorylation is required 
for interaction with its known partner, SHIP1. Indeed, when the tyrosine residues of 
Dok3 were mutated to phenylalanine, Dok3 binding to SHIP1 was abrogated (Robson 
et al., 2004). In the same study, Dok3 directly inhibited JNK activation via SHIP1 
however the other known substrates of SHIP1 such as AKT activation appeared 
unaffected. Therefore this suggests other novel negative signaling pathways in BCR 





Dok3 was also demonstrated to interact with Grb2 (Honma et al., 2006). This novel 
interacting partner was sequenced from immunoprecipitated lysates that were co-
expressed with Dok3 and SRC in HEK293T cells. Further biochemical studies 
including site-directed mutagenesis identified the tyrosine phosphorylation sites of 
Dok3 responsible for binding to Grb2. The tyrosine 398 and tyrosine 432 sites on 
Dok3 has to be phosphorylated by SRC to allow Dok3 binding to the SH2 domain of 
Grb2. The authors envisaged that as Grb2 can form a stable complex with son-of-
sevenless (SOS), therefore Dok3 may be required to sequester the Grb2-SOS complex 
from Shc to inhibit downstream RAS-ERK pathway (Honma et al., 2006). 





 signalling was found to be enhanced in Grb2-deficient DT40 cells upon BCR 
crosslinking (Stork et al., 2007). The authors hypothesized that since Dok3 binds to 
Grb2, they may function in the same regulatory manner. Indeed, when Dok3-deficient 
DT40 cells were generated and analyzed for Ca2
+
 activation upon BCR crosslinking, 
they were found to be enhanced as compared with wildtype DT40 cells treated 
similarly (Stork et al., 2007). This phenotype was consistent with that of Grb2-
deficient DT40 cells. Furthermore the mechanistic role of Dok3 in Ca2
+
 signaling has 
been investigated in detail. When tyrosine 331 residue was mutated in Dok3, it 
abolished binding to Grb2 which led to a defective Ca2
+
 flux. Also, this amino acid 
residue is indispensible for Dok3 interaction to SHIP1 (Stork et al., 2007). As SHIP1 
was already known to be a negative regulator of BCR-induced Ca2
+
 flux, it was 
tempting to assume that Dok3 exerts its negative effects of BCR-induced Ca2
+
 flux 
via SHIP1 and Grb2. However subsequent experiments revealed that in Dok3-
deficient DT40 cells, SHIP1 phosphorylation was unaffected by BCR ligation but 




concluded that Dok3 and SHIP1 interaction and the signalling event which leads to 
Ca2
+
 flux upon BCR ligation were mutually exclusive in DT40 cells. Dok3 together 
with Grb2 negatively regulated PLC2-mediated Ca2+ flux in BCR signalling in 
DT40 cells (Stork et al., 2007).  
 
Finally, Dok3-deficient mice were generated in our laboratory and upon analysis with 
respect to B cell development and signalling via BCR, we found that Dok3 is non-
redundant in B cell receptor signalling, as the phenotype of Dok3
-/-
 mice is 
distinguishable from Dok1
-/-
 mice. The data from the analysis of Dok3
-/-
 mice in B cell 
development and activation showed that although the mice exhibited normal B cell 
development, normal T-dependent immune response and germinal centre formation 
had enhanced basal serum IgM and were hyper-responsive toward T-independent 
Type I and type II antigen. In the in vitro studies of Dok3 in BCR signalling, the 
mutant B cells were hyperproliferative and induced a higher level of Ca2
+
 flux 
compared to wildtype controls upon BCR crosslinking. The major signal transduction 
pathways were examined and Dok3 was shown to inhibit the activation of NFB and 
MAPK including JNK and p38 as well as the activation of SHIP1 but not its 
translocation to lipid raft  (Ng et al., 2007). In conclusion Dok3 played a negative 
regulatory role in some aspects in BCR signalling and suggested that there could be 
compensatory functions mediated by Dok1. This hypothesis may be tested by the 








1.7.2 Tyrosine kinases that can potentially phosphorylate Dok3  
Tyrosine kinases are catalytic enzymes that are able to transfer a phosphate group 
from ATP to a protein in the cell. The accepting protein is defined as the substrate.  
The mode of action allows the tyrosine kinase to function perpetually as a molecular 
“switch” that can turn on or off many cellular functions as a result of the signal 
transduction events that follow when the enzyme is active (Hanks et al., 1988). 
 
When tyrosine kinase functions abnormally such as in a mutated form where it is 
constitutively switched “on”, it is possible to result in cancerous events where cells 
are dividing in an unrestricted and proliferative manner owing to disregulated signal 
transduction pathways responsible for cell division (Gunby et al., 2007). Parts of 
effective cancer treatments that are currently under clinical trials include those of 
tyrosine kinase inhibitors. An example of one such drug is PCI-32765 which is a BTK 
inhibitor for the treatment of B cell lymphoma (de Rooij et al., 2012). Other kinase 
inhibitors that are already approved drug therapies in the pharmaceutical market 
include Imatinib for the treatment of CML (Kantarjian et al., 2011) 
1.7.2.1 c-Abelson tyrosine kinase 
While Abelson tyrosine kinase (c-Abl; Abl1) is a member of the tyrosine kinase 
family, the Abl family of non-receptor tyrosine kinase beside c-Abl, also includes its 
paralogue, the Abl-related gene (Abl2) (Hanks et al., 1988). The structure of c-Abl 
comprises a tyrosine kinase domain, a SH2 and a SH3 domain as well as a „CAP‟ 
region present in the amino terminus of the protein (Superti-Furga and Courtneidge, 
1995). c-Abl is activated similarly to SRC-family kinases in that it is kept in an 




access to its substrate (Superti-Furga and Courtneidge, 1995). c-Abl is activated when 
its interacting protein partners bind to its regulatory domains which release c-Abl 
from the inhibitory conformation. A free c-Abl is then able to carry out its enzymatic 
activity and begins to add phosphate groups to its signalling substrate (Smith and Van 
Etten, 2001). c-Abl functions have to be tightly regulated as it is implicated in many 
cellular processes including cell growth and differentiation, oxidative stress and 
DNA-damage, actin filaments reorganization and cell migration (Hernandez et al., 
2004). One chromosomal aberration that is well characterised in disregulation of c-
Abl function is bcr-Abl (Ren, 2005). This is formed by a chromosomal translocation 
between two chromosomes. For example, the fusion of c-Abl with the Bcr gene leads 
to the formation of the BCr-Able oncogene.  
 
Bcr-Abl is devastating in two ways. Firstly, Bcr-Abl results in a new protein folding 
structure and owing to some perturbations, the regulatory domain of the original c-
Abl protein does not function any more to keep itself in an inhibited state and the Bcr-
Abl protein becomes uncontrollable (Ren, 2005). Secondly, because of the fact that 
four of the Bcr-Abl chains are now formed in close proximity, it became effortless for 
the kinase to carry out catalytic activity on its substrates. Bcr-Abl perpetually self-
activates other Bcr-Abl proteins and this result in hyperactivity and constitutive 
positive signalling. Unregulated growth of blood cells happens as a result and leads to 
CML (Nowell, 2007). Fortunately it was the intensive research that was carried out on 
drug screening that Imatinib was discovered to be able to block the kinase site of Bcr-





1.7.2.2 Bruton’s tyrosine kinase  
Bruton‟s tyrosine kinase (BTK) is a member of the Tec family of kinases that plays a 
critical role in B cell maturation and activation, activation via Toll-like receptors in 
macrophages and dendritic cells as well as mast cell activation through the high-
affinity immunoglobulin E receptor (IgE) receptor (Mohamed et al., 1999). Mutations 
in the BTK gene resulted in the development of primary immunodeficiencies X-linked 
agammaglobulinemia (XLA) in humans (Lee et al., 2010) and X-linked 
immunodeficiency (Xid) in mice (Lindvall et al., 2004). Human XLA patients have 
normal pre-B cell populations in their bone marrow but severely compromised mature 
B cell numbers in secondary lymphoid organs and circulating blood. They are 
incapable of producing antibodies and are consequently presented with recurrent 
bacterial and enteroviral infections, as over 800 such cases have been reported 
(Fruman et al., 2000). But the effects of many of these on the normal physiology of 
relevant immune cells and the specific contribution to the XLA or Xid phenotype are 
still unclear. This is in part due to the hitherto limited knowledge of which signalling 
molecules interact with BTK when different immune receptors are engaged, and also 
for assembling what is called the BTK interactome or signalosome, although several 
signalling partners such as spleen tyrosine kinase (SYK), the adapter protein B-cell 
linker protein (BLNK) and phospholipase C2 (PLC2) are well established  
(Satterthwaite and Witte, 2000). Besides its extensively characterised role in B cells, 
BTK has been shown to be involved in Fc-receptor I-mediated mast cell 
degranulation and cytokine production (Hata et al., 1998). However, the role of BTK 
in lymphomagenesis is more controversial as different studies described the presence 
or absence of inactivating mutations of BTK in lymphoid tumours. The most 




in which combining this null mutation with BTK deficiency potentiates tumor 
development (Kersseboom et al., 2006). Taken together, it is therefore not only of 
immense biological but also clinical interest to identify the signalling molecules 
which constitute the BTK interactome in different immune cell types activated via 
different receptors. It was demonstrated that Dok proteins could interact with BTK 
and Grb2 in BCR signalling and hence make BTK a likely tyrosine kinase candidate 
that possibly phosphorylates Dok family proteins in certain receptor signalling 
systems (Stork et al., 2007). Structurally, BTK contains multiple protein-protein 
interaction domains.  It has a N-terminal Pleckstrin homology (PH) domain for 
membrane localization following its activation, and also a Tec homology (TH) 
domain as well as SRC-homology 2 (SH2), and a C-terminal SH3 domain binding 
proline-rich sequences and a SH1 kinase domain.  In addition, BTK possesses 
multiple tyrosine phosphorylation sites (Lindvall et al., 2005). 
1.7.2.3 Lyn 
Among the tyrosine kinase proteins, Lyn is one in the SRC-family kinase. The 
function of Lyn has been a subject of controversy in the B cell immunology for a long 
time. It is generally accepted that Lyn is the tyrosine kinase that first initiates BCR 
signalling by phosphorylating the Igα and Ig ITAM motifs upon activation. 
Interestingly, Lyn is kept in an inhibitory state by autophosphorylation in tyrosine 507 
residue and phosphorylation of tyrosine 416 residue instead of relieving its inhibition 
and allowing activation to occur where it can carry out its intrinsic enzymatic activity 
(Hibbs and Dunn, 1997). The majority who have studied Lyn accept its identity as a 
positive regulator. However, the studies with Lyn-deficient mice have challenged this 
paradigm. Lyn
-/-




in the normal Mendelian ratio, however developed autoimmunity at a later age. This 
strongly suggests a negative regulatory role for Lyn, as this phenotype closely mimics 
known negative regulatory proteins (including SHP1, SHP2 and SHIP1) in knockout 
mice. (Nishizumi et al., 1998). 
 
In these mutant mice, the B lymphocytes exhibited increased Ca2
+
 flux and 
proliferative responses upon BCR ligation as well as enhanced levels of 
autoantibodies as compared to its wildtype counterparts (Tsantikos et al., 2010). It is 
however notable that Lyn-deficiency does not affect B cell developmental stages in 
the bone marrow suggesting that other SRC-family kinase (SFK) may compensate for 
Lyn absence in this specific developmental regulatory role of B lymphocytes (Meade 
et al., 2002). One other possibility is Lyn‟s redundancy in this aspect of B cell 
maturation as studies have showed that SYK (a critical kinase downstream of BCR 
signalling) is known to also phosphorylate the Igα and Ig of the BCR (Cornall et al., 
2000). These findings therefore indicate a multi-faceted role for Lyn and suggest that 
although Lyn‟s positive regulatory function may be redundant and could be replaced 
by other SFKs, Lyn‟s negative regulatory function is nonetheless indisputable and 
indispensable for some of its downstream signal transduction effects of BCR leading 
to cellular functions of B lymphocytes. Lyn was demonstrated to phosphorylate a 
negative co-receptor CD22 on the cell surface, which in turn can recruit SHP1. SHP1 
belongs to the family of tyrosine phosphatase, which include SHP-2, and SHP-1 
functions to inhibit on-going signalling events in BCR activation by 
dephosphorylating the positive effector proteins. These effector proteins include SYK, 
PLC and BLNK (Kurosaki, 2002). More recently, it was demonstrated that Lyn 




these proteins is the Dok family proteins. When Dok family proteins are 
phosphorylated by Lyn, they in turn interact with the SH2 domain of SHIP1 and 
rasGAP to exert its inhibitory effects including the activation of ERK MAPK 
(Yamanashi et al., 2000). 
1.8 Aim of research 
Most investigations on TLRs have focused on cells of the innate system. These 
include professional antigen-presenting cells (APCs) such as dendritic cells and 
macrophages. Our previous study demonstrated that Dok3 played a critical role in 
BCR signalling in B cells by functioning as a negative regulator (Ng et al., 2007). 
However, Dok3 is also highly expressed in macrophages (Mashima et al., 2009) and it 
is not known if Dok3 has a role in TLR signalling. Since TLR signalling is complex, 
it may be possible that more molecules could be involved in their signal transduction 
pathways. We therefore hypothesise that Dok3 might play a novel role in TLR 
signalling in macrophages. This hypothesis is further supported by findings that Dok1 
and Dok2 have been demonstrated as negative regulators in LPS signalling. Thus 
Dok3 may also participate in some as yet undefined way in TLR signalling in 
macrophages. 
 
The main aim of the research is to determine if Dok3 is involved in TLR signalling. 
This was accomplished by dissecting the signal transduction pathways of Dok3 in 
TLR3-mediated activation pathways leading to the production of inflammatory 
cytokine and other cellular aspects of host innate immune response. 
The results will hopefully provide new insights into the complexities of TLR 
signalling and identify Dok3 as a central molecular target for therapeutic intervention 
against microbial and viral infection, sepsis and autoimmunity. 
MATERIALS AND METHODS 
II-47 
 
CHAPTER II. MATERIALS AND METHODS 
 




2.1.1 Reagents, Buffers and Cell culture media  





iNOS  AACGGAGAACGTTGGATTTG CAGCACAAGGGGTTTTCTTC 
TNF  TCCCAGGTTCTCTTCAAGGGA GGTGAGGAGCACGTAGTCG
G 






Table II.1 Sequences of primers used in RT-PCR. 
 
Gene Primer Sequence 5’-3’ Vectors 
DOK3F CGGGATCCATGGAGTCTGTGGAGCC  PXJ40 
DOK3R CCCAAGCTTTCAGGGCCGGTCAC PXJ40 
D1F ATAGGATCCGAGTCTGTGGAGCCCCCG PXJ40 
D1R ATAAAGCTTTCACGGGAAGGCCAGCTGACA PXJ40 
D2F ATAGGATCCGAGTCTGTGGAGCCCCCG PXJ40 
D2R ATAAAGCTTTCACCGCTGGCGGGCAATGGC PXJ40 
D3F ATAGGATCCGCCACCGAGCGTCTTCCAGAGCTG PXJ40 
D3R ATAAAGCTTTCACCGCTGGCGGGCAATGGC PXJ40 
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D4F ATAGGATCCGCCACCATGGGTACCGGAGAATGTTCG PXJ40 
D4R ATAAAGCTTTCATCAGGGCCGGTCACAGGG PXJ40 
D5F ATAGGATCCGCCACCATGGAGTCTGTGGAGCCC PXJ40 
D5R ATAGGATCCGCCACCATGGGTACCGGAGAATGTTCG  PXJ40 
TBK1F ATAGGATCCCAGAGCACCTCCAACCAT PXJ40 
TBK1R ATACCCGGGCTAAAGACAGTCCACATTGCG PXJ40 
TRAF3F ATAGGATCCGAGTCAAGCAAAAAGATG PXJ40 
TRAF3R ATACCCGGGTCAGGGGTCAGGCAGATCCGA PXJ40 
Luc-IFNbF ATACCCGGGGGCTTTTCAGTGGACACT pGL3-Basic 
Luc-IFNbR ATAAAGCTTGCAGTGAGAATGATCTTC pGL3-Basic 
Table II.2 Gene-specific primers and plasmid constructs used in this thesis. 
 
Cytokine Company Application 
IL6 BD Pharmingen ELISA 
IL12p40 BD Pharmingen ELISA 
TNFα eBioscience ELISA 
Table II.3 Recombinant cytokines used for ELISA. 
 
Cell Culture Media Component Concentration 
General Culture 
 
DMEM (4500 mg/ml glucose)  NA 
Fetal calf serum 10 % 
L-glutamine  2 mM 
penicillin/streptomycin 100 units/m 
non-essential amino acids  100 mM 
sodium pyruvate 1 mM 
MATERIALS AND METHODS  
II-50 
 
-mercaptoethanol 5 mM 
BMM Culture M-CSF L929 supernatant 30 % 
Fetal calf serum 20 % 
L-glutamine  2 mM 
penicillin/streptomycin 100 units/m 
non-essential amino acids  100 mM 
sodium pyruvate 1 mM 
-mercaptoethanol 5 mM 
Table II.4 Component specification for cell culture media used in this thesis.  
All solutions are filter-sterilized and stored at 4°C. 
 




Glucose 10 mM 
EDTA, pH 8.0 3 mM 
PBS NA 
Red Blood Cell Lysis 
Buffer 
NH4Cl 0.15 M 
KHCO3 1 mM 
EDTA, pH 8.0 0.1 mM 
H2O NA 
Table II.5 Component specification for cell culture buffers used in this thesis.  
All solutions are filter-sterilized and stored at 4°C. 
 
Reagents Component Concentration 
10 X DNA loading dye Bromophenol blue  0.1 %  
Xylene cyanol 0.1 %  
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Glycerol 40%  
5X Protein Loading dye  Tris-HCl, pH 6.8 0.25M 
SDS 15% 
Glycerol  50% 
β-mercaptoethanol 25% 
Bromophenol blue 0.01% 
Phospho-lysis buffer Tris-Cl, pH 8.0 10 mM 
EDTA, pH 8.0 1 mM 
NaCl 150 mM 
NP-40 1 % 
Triton-X buffer Tris-Cl, pH 7.5 15 mM 
NaCl 150 mM 
EDTA 5 mM 
Triton-X 0.1 % 
Table II.6 Reagents required for gel electrophoresis. 
All reagents are stored at room temperature. 
 
Name Company Species Working dilution 
A20 Santa Cruz Goat 1:1000 
ABIN1 Cell Signalling Rabbit 1:1000 
AKT Cell Signalling Rabbit 1:1000 
BTK Santa Cruz Goat 1:1000 
COX2 Cayman chemical Mouse 1:1000 
Dok3  Santa Cruz Goat 1:500 
Dok3  Santa Cruz Rabbit 1:1000 
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ERK2  Santa Cruz Rabbit 1:1000 
FLAG Sigma Rabbit 1:1000 
HA Sigma Mouse 1:1000 
HDAC-1  Santa Cruz Rabbit 1:1000 
IB  Santa Cruz Rabbit 1:1000 
IRF3  Santa Cruz Rabbit 1:1000 
JNK1 Santa Cruz Rabbit 1:1000 
p105 Santa Cruz Goat 1:1000 
p38 Santa Cruz Rabbit 1:1000 
Phospho-AKT (Thr308) Cell Signalling Rabbit 1:1000 
Phospho-AKT (S473) Cell Signalling Mouse 1:1000 
Phospho-ERK  Santa Cruz Mouse 1:1000 
Phosphotyrosine  
HRP-conjugated (4G10) 
Upstate Mouse 1:5000 
Phospho-IRF3 (S396) Cell Signalling Rabbit 1:1000 
Phospho-SAPK/JNK  
(Thr183/Tyr 185) 
Cell Signalling Rabbit 1:1000 
Phospho-p38 Cell Signalling Rabbit 1:1000 
Phospho-TBK1 (S172) BD Pharmingen Mouse 1:1000 
TBK1 Cell Signalling Rabbit 1:1000 
TNF Santa Cruz Goat 1:1000 
TPL-2 Santa Cruz Goat 1:1000 
TRAF3 Cell Signalling Rabbit 1:1000 
TRIF IMGENEX Rabbit 1:1000 
Table II.7 List of antibodies used in this thesis. 




Ligand Type Company 
LPS E. coli O111:B4 Sigma 
poly(I:C) Synthetic (HMW) InvivoGen 
Poly(I:C)/LyoVec™ Synthetic (HMW) InvivoGen 
Table II.8 Ligands used to stimulate cells. 
 
Cell lines Company 
Raw264.7 ATCC 
HEK 293T ATCC 
L929 Sigma 
Table II.9 List of cell lines used in this thesis 
 
2.1.2 Viruses 
Influenza A virus, IVR-116 (A/New Caledonia/20/99 (H1N1) x IVR-6 (H3N2), 
NIBSC code 06/108) was obtained from the National Institute for Biological 
Standards and Control, United Kingdom. 
2.1.3 Mouse Strains 
Wildtype C57BL/6 and Dok3
-/-
 mice were obtained from Biological Resources Centre 




 mice were bred and housed in the BRC 
facilities.  Experiments with mice were performed according to guidelines issued by 





 mice were kindly provided by Dr. Shizuo Akira (Osaka 
University, Japan). 




2.2.1 Characterisation of the effect of Dok3 deficiency on antiviral 
response in vivo 
For the measurement of poly(I:C)/LPS-induced septic shock, wildtype and Dok3
-/-
 
mice (6-8 weeks old) were injected intraperitoneally with 12.5 g of poly(I:C) or 10 
ng LPS with 20 mg of D-GalN (Sigma). The dose of poly(I:C) and LPS was 
calculated per 20 g of body mass. Survival was monitored for more than 32 hours. 
2.2.2 Characterisation of Dok3 deficiency in vitro 
2.2.2.1 Bone marrow-derived macrophage culture 
Bone marrow cells were obtained by injecting culture media into the femur and tibia. 
All cells were spun down by centrifuging at 1000 rpm for 5 mins at 4 
o
C. To eliminate 
erythrocytes, cells were treated with 1 ml of red blood cells lysis buffer for 5 mins by 
incubating on ice. The cells were washed in 10 ml culture media and collected by 
centrifuging at 1000 rpm for 5 mins at 4 
o
C. Bone marrow cells were counted using 
haemocytometer and 10
6
cells were plated on 10cm culture plate containing 10ml of 
BMM culture media.  
2.2.2.2 TLR ligand Stimulation  
After 6 days of culture BMM were harvested using macrophage detach buffer and 
plated according to the assay performed. BMM were incubated for 24hrs and 
stimulated with poly(I:C) [50ug/ml] or LPS [10-100ng/ml]. 
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2.2.2.3 Virus infection 
Influenza A virus was propagated 3 times in Vero cells (ATCC CCL-81) in OptiPro 
SFM (Invitrogen, Grand Island, NY, Cat. No. 12309-019) supplemented with 5 g/ml 
porcine trypsin (Sigma-Aldrich, St. Louis, MO, Cat. No. T5266, 1500 BAEE unit/mg) 
and subsequently stored at -80 
o
C. The virus was then thawed at room temperature 
and used to infect WT  and Dok3
-/- 
primary  macrophage cells in OptiMEM 
(Invitrogen) at a multiplicity of infection (MOI) of 10 TCID50/cell for 3, 6, 12 or 24 
hours. The experiment was performed in triplicate. Total RNA was extracted from 
virus-infected cells using TRIzol (Invitrogen). 
2.2.2.4 Enzyme-Linked Immuno-Sorbent Assay (ELISA) 
Prior to incubation with biotinylated detection antibodies (BD Pharmingen) samples 
were washed in PBS containing 0.05% Tween-20, followed by streptavidin-coupled 
horseradish peroxidase secondary antibody. Finally BD OptEIA detection reagent 
(Becton Dickinson) was applied and colorimetric changes were quantified by 
measuring absorbance at 450 nm with a TECAN Genios multi-plate reader. The 
concentrations of IL-6, TNF, IL-12p40 were determined using commercial ELISA 
kits. 
2.2.2.5 Quantitative RT-PCR 
Cells were lysed and homogenized by passing through 26G needles in 1ml of Trizol 
(Invitrogen Cat. No. 15596-026). The homogenized mixture was incubated at room 
temperature for 5 min to ensure complete dissociation of nucleoprotein complexes. 
200 l of chloroform was then added to the mixture and tubes were vortexed before 
incubation at room temperature for another 2 min. The tubes were centrifuged at 
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12,000 rpm at 4C for 15 min. After centrifugation, the upper aqueous layer was 
collected in a clean tube and 500 l isopropyl alcohol was added, mixed and 
incubated at room temperature for 10 min. The tubes were centrifuged again at 12,000 
rpm at 4C for 10 min. The RNA pellet was washed with 70% ethanol and allowed to 
air dry before dissolving in RNAase-free water. The first strand cDNA synthesis was 
done using Superscript
TM
 III First-Strand Synthesis System for RT-PCR (Invitrogen, 
Cat. No. 18080-051) according to the manufacturer‟s protocol. Briefly, the following 
mixture was prepared in sterile PCR tubes for each reaction of 5 g of RNA: Total 
RNA was extracted from wildtype and Dok3
-/-
 cells using an RNeasy Mini kit 
(Qiagen) and cDNA was synthesized with Superscript II reverse transcriptase as per 
manufacturer‟s protocol (Invitrogen). Quantitative PCR was performed on Applied 
Biosystems 7500 real-time PCR system using specific primers and SYBER green 
(Applied Biosystems). 
2.2.2.6 Western blotting  
Cells were lysed on ice for 30 mins in a phospho-lysis buffer containing 1% NP40, 10 
mM Tris-HCl pH8.0, 150 mM NaCl, 1 mM EDTA, 0.2 mM Na3VO4 and a cocktail of 
protease inhibitors (Roche) and sonicated. Cell homogenates were centrifuged at 
13,000 rpm for 15 min at 4
0
C and supernatants were recovered for protein 
quantification by BCA protein assay kit (Pierce). 30 µg of whole cell lysates or 5 µg 
of nuclear extracts were electrophoresed in 10% SDS-polyacrylamide gels and 
transferred onto immunoblot polyvinylidene difluoride membranes (Millipore, MA). 
The membranes were blocked with 5% non-fat milk in Tris-buffered saline containing 
0.1% Tween 20 for 1 hr at room temperature and incubated separately with the 
various antibodies that recognized the different molecules being studied. Protein 
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bands were visualized using horseradish peroxidase-coupled secondary antibodies and 
the enhanced chemiluminescence detection system (Amersham Pharmacia Biotech). 
Densitometric
 
analyses of protein bands was carried out using Bio-Rad Imaging 




) was normalized to the corresponding
 
total protein and 
expressed as -fold increase in intensity over
 
the control non-stimulated samples.  
2.2.2.7 Immunoprecipitation 
For immunoprecipitation studies, antibodies were first coupled to Protein A/G Plus-
Agarose (SC-2003, Santa Cruz) at 4 °C overnight. The beads were washed twice in 
lysis buffer and incubated with pre-cleared cell lysates for 1 h at 4 °C. Subsequently, 
beads were boiled in a loading buffer for 5 min to release the proteins. The released 
proteins were resolved in SDS-polyacrylamide gels as described in Western blotting. 
2.2.2.8 Nuclear translocation Assays 
For analysing translocation of proteins to the nucleus, 5ug of nuclear extracts from 
cells that were stimulated with LPS and Poly(I:C) for an hour were isolated using 
Nuclear and cytoplasmic Extraction Reagents kit (Pierce Biotechnology, USA) prior 
to immunoblotting. Tubulin and HDAC1 were used as markers for cytosolic and 
nuclear fractions separately and respectively. 
2.2.3 Mass spectrometric analysis 
BMM cells were stimulated with LPS or poly(I:C) and lysate and then subjected to 
endogenous immunoprecipitation using Dok3 antibody. After the SDS-PAGE 
proteins were visualised by Coomassie Brilliant Blue staining the band of interest 
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were excised. Proteins in gel were washed, trypsin digested and MS analysis were 
performed in a similar manner according to (Senis et al., 2009). 
2.2.4 Molecular Cloning  
2.2.4.1 Polymerase chain reaction 
To clone DNA fragments PCR reactions were carried out using gene specific primers 
and DNA polymerase (Finnzyme) according manufacturer‟s protocol. Thermal 
cycling was performed according to thermal profile below: 
 
Step Temperature Time Cycles 
Initial denaturation 94 
o
C 1 mins 1 
Denaturation 94 
o
C 30 s  
30-35 Annealing 50 to 60 
o
C 30 s 
Extension 72 
o
C 30 s 
Final extension 72 
o
C 10 mins 1 
Cooling 4 
o
C Infinite time  
2.2.4.2 Agarose gel electrophoresis 
To cast a 1 % (w/v) agarose gel, 1 g of agarose was added to 100 ml 1 X TAE and 
microwaved till the agarose melted. Then 0.5 g/ml ethidium bromide was added to 
the melted agarose, poured into a gel casting apparatus and allowed to solidify. 10 X 
DNA loading dye was added to DNA samples to a final 1 X working concentration, 
loaded into gel submerged in 1 X TAE buffer and electrophoreses at 120 volts for 30 
mins. The separated DNA bands were visualized using UV trans-illuminator and 
photographed for the record. 
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2.2.4.3 Restriction digestion of DNA 
To clone DNA fragments into a mammalian expression vector, both vector and insert 
DNA were cut with the appropriate restriction enzymes. The restriction digestion was 
set up as follows:  
Components  Stock concentration 1X Reaction 
DNA template  1 g/l 1 l 
Reaction Buffer 10X 2 l 
Restriction enzyme(s) 10 u/μl 1l 
BSA 10 mg/ml 0.3  
Water NA 15.6l 
 Total Volume 20 l 
 
Reaction mix was incubated in 37 
o
C water bath for at least 1 hour. The genomic 
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2.2.4.4 Ligation of DNA 
Ligation of the vector for DNA insertion was carried out as follows: 
Components  Stock concentration 1X Reaction 
vector DNA 1 g/l 0.2 l 
insert DNA 1 g/l 0.8 l 
Reaction buffer 10 X 2 l 
T4 DNA Ligase  400 units/l 1  
Water NA 16 l 
 Total Volume 20 l 
 
Reaction mix was incubated at 16 
o
C overnight or 37 
o
C water bath for at least 1 hour. 
 
2.2.4.5 Transformation of DH5 by heat shock method 
DH5 competent cells (50µl) was added into the ligation mixture and incubated on 
ice for 30 mins. Next, the DNA-DH5 mix was immersed into a 42 oC water bath for 
90 seconds and immediately chilled on ice for a further 1 min. The transformed cells 
were allowed to recover from heat shock by the addition of 1 ml of antibiotic-free LB 
broth and incubated in a 37 
o
C water bath for at least 30 mins. Finally, the 
transformants were centrifuged at 3000 rpm, resuspended in 200 l of antibiotic free 
LB and plated onto selection agar and incubated overnight at 37 
o
C. 
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2.2.4.6 Bacterial DNA mini-/maxi-prep by alkaline lysis 
Antibiotic-resistance transformants were inoculated into 2 ml selection LB broth and 
grown overnight by shaking at at 37 
o
C. 1.5 ml of overnight culture was collected by 
centrifugation at 14000 rpm in an eppendorf tube. Mini scale plasmid DNA was 
prepared using Qiagen Plasmid mini-prep Kit according to the manufacturer‟s 
protocol. Large scale plasmid DNA was also prepared using Qiagen Plasmid Maxi-
prep Kit according to the manufacturer‟s protocol. 
2.2.4.7 DNA sequencing 
DNA sequencing was carried out using Bigdye Version 3 according to the 
manufacturer‟s protocol. After sequencing PCR cycle reaction mixture was purified 
using capillary electrophoresis and sequenced using Applied Biosystems 3730xl 
instrumentation and BigDye terminator chemistry.  
2.2.5 Protein interaction studies using overexpression system 
2.2.5.1 Transfection of HEK293T and RAW264.7 cell lines 
For transient transfection of HEK293T or RAW264.7 cells, Lipofectamine 2000 
(Invitrogen) or FuGENE was used and the transfection was done as according to the 
manufacturer‟s protocol. Briefly, approximately 2 x 106 cells were added onto each 
well of a 6-well plate 24 hours prior to transfection. Approximately 1 g of DNA was 
added into a sterile microcentrifuge tube with 250 l of OptiMEM. The solution was 
mixed and then followed by quick spin to collect the material and incubated at room 
temperature for 5 min. Subsequently 10 l of Lipofectamine in OptiMEM was added 
to the mixture followed by gentle mixing before drawing the sample which was then 
incubated at room temperature for 20 min to allow the formation of the transfection 
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complex. Culture media was removed from the cells and 1.5 ml of fresh media was 
added. To each of the transfection mixture, 400 l of media was added and the 
mixture was aggregated by gently pipetting up and down before adding to the cells in 
a drop-wise manner. 
2.2.5.2 Confocal microscopy  
Cells were washed twice with cold PBS with 1% BSA (PBS/1%BSA) and fixed 20 
min on ice with 4% paraformaldehyde in PBS. After permeabilization in 0.2% 
saponin-0.03M sucrose in PBS/1%BSA at room temperature for 10 min, the cells 
were washed twice with cold PBS. The cells were blocked with 5% normal goat 
serum in PBS/1%BSA room temperature for 1 hr before incubation with primary 
antibodies overnight at 4C. The slides were washed three times with PBS/1% BSA, 
incubated for 1 hr at room temperature with Alexa 546 goat anti-mouse and Alexa 
488 chicken anti-anti-rabbit to reveal the respective primary antibodies. The slides 
were washed three times with PBS/1%BSA, mounted and viewed under a confocal 
laser scanning microscopy (Olympus).  
2.2.5.3 Luciferase Assay 
HEK293T cells seeded on 48-well plates (10
5
cells/well) were transfected with 100ng 
of luciferase reporter vector controlled by the IFNβ promoter together with a total of 
500ng of different expression vectors or control vector as well as 2ng of Renilla-
luciferase reporter gene for internal control. Approximately twenty-four hours later 
cell were harvested and luciferase activity in the total cell lysate was analysed using 
Luciferase Reporter Assay System kit (Promega).  




Statistical analysis was performed using an unpaired student t test (Prism; Graph Pad 
Software, San Diego, CA). All p values less than 0.05 were considered significant and 
marked with an asterisk *. Survival curves (Kaplan-Meyer plots) were compared 
using a log-rank test. Final mortality rates (deaths per total) were compared with Chi-
square test.  
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CHAPTER III. ROLE OF DOK3 IN TLR3 SIGNALLING IN 
MACROPHAGES 




Toll-like receptors (TLR) are innate immune receptors that recognise PAMPs found 
on microbes and activate signalling pathways that induce the expression of immune 
and inflammatory genes in the host (Takeda and Akira, 2005). There are altogether 11 
TLRs in humans and 13 in mice (Takeda and Akira, 2005). Of these, TLR3 is 
involved in the anti-viral response by recognizing dsRNA, a replication intermediate 
of numerous viruses (Vercammen et al., 2008). In particular, TLR3 has been 
implicated in the host response to influenza, dengue, SARS coronavirus and other 
respiratory viruses (Tsai et al., 2009; Vercammen et al., 2008). TLR3 engagement by 
dsRNA or poly(I:C) triggers the secretion of inflammatory cytokines such as IL-6 and 
TNF and more importantly, IFNβ (Alexopoulou et al., 2001). TLR3 is also involved 
in inflammatory responses by detecting host-derived nucleic acids (Bernard et al., 
2012; Cavassani et al., 2008). TLR3 signals via the adaptor TRIF, and induces the 
formation of the TRAF3/TBK1 complex that subsequently activates the transcription 
factor IRF3, which is necessary for interferon gene expression (Hiscott and Lin, 
2005). Despite this, much remains unknown in terms of TLR3 signalling. It is 
postulated that there could be other as yet to be discovered signalling molecules 
involved in TLR3 signal transduction. A detailed understanding of the TLR3 signal 
transduction pathways could yield novel molecular targets that are amenable for the 
development of therapeutic drugs such as those that could enhance the antiviral 
response or those that could dampen the induction of any potential “cytokine storm” 
that would be detrimental to the host. Since TLR signalling is complex, we 
hypothesized that more molecules are therefore involved. 
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In contrast to other Dok family members, there are no studies investigating the role of 
Dok3 in TLR3 signalling. Previous studies have revealed negative regulatory roles of 
Dok1 and Dok2 in TLR4 signalling (Shinohara et al., 2005). Using Dok3-knockout 
mice our laboratory generated, the characterisation of Dok3 indicated that it played an 
inhibitory role in BCR signalling (Ng et al., 2007).  DOK3 was shown to be tyrosine 
phosphorylated upon B-cell antigen receptor engagement (Ng et al., 2007). Because 
Dok1 and Dok2 were known to to be also tyrosine phosphorylated and regulate TLR 
in macrophages, we hypothesized that Dok3 may be involved in TLR regulation as 
well. We hence investigate if Dok3 may play a role in TLR signalling in 
macrophages. To confirm this we assessed wildtype and Dok3-knockout macrophages 
abilities to produce inflammatory cytokines in response to poly(I:C) challenges. 
 
We also examined the possible signalling pathways that might be affected by Dok3 
deficiency in TLR3 signaling in macrophages in many of our subsequent experiments. 
Lastly we examined the mechanistic role of Dok3 in TLR3 signal transduction. 
3.2 Dok3 is phosphorylated upon poly(I:C) stimulation of macrophages 
Tyrosine phosphorylation of Dok family members is known to precede its effector 
role as adaptor an protein (Lemay et al., 2000). To determine if Dok3 is involved in 
TLR3 signalling in macrophages, we investigated if Dok3 undergoes tyrosine 
phosphorylation upon poly(I:C) treatment. We treated wildtype macrophages with 
poly(I:C) that was recognised by TLR3. As shown in Figure III-1, Dok3 undergoes 
tyrosine phosphorylation upon poly(I:C) stimulation. The tyrosine phosphorylation of 
Dok3 was not evident in the untreated cells. Next we examined if the TRIF adaptor 
protein is required for Dok3 tyrosine phosphorylation. This is because TRIF is known 
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to be the only adaptor protein that is solely used by TLR3 in contrast to the other 
TLRs which also uses MyD88 (Yamamoto et al., 2003). We show here in Figure 
III-2, that Dok3 phosphorylation was impaired as a result of TRIF deficiency. The 
data taken together suggest that Dok3 undergoes tyrosine phosphorylation upon TLR3 
signalling and may possibly be involved in the signal transduction pathways activated 
downstream of TRIF.  
 
Figure III-1 Dok3 is phosphorylated in macrophages upon poly(I:C) stimulation.  
Bone marrow-derived macrophages (BMM) were stimulated for various times as indicated with 50 
g/ml poly(I:C) and subsequently lysed. Dok3 was immunoprecipitated and probed with anti-








 BMM were stimulated with 50 g of poly(I:C) for 30 mins and subsequently 
lysed. Lysates were immunoprecipitated with Dok3 antibodies and subsequently immunoblotted 
probed with anti-phospho-tyrosine (pY) or anti-Dok3 antibodies. Figure shown is representative of two 
independent experiments. 
ROLE OF DOK3 IN TLR3 SIGNALLING IN MACROPHAGES  
III-68 
 
3.3 Dok3 deficiency affects cellular response to poly(I:C) in vivo and in vitro 
It has been demonstrated that TLR3 is the receptor involved in the inflammatory 
response of mice challenged with poly(I:C) (Alexopoulou et al., 2001). To determine 
if Dok3 plays a role in mediating the inflammatory effects of poly(I:C)-induced 
activation of TLR3, we employed a septic shock model by challenging wildtype and 
Dok3-deficient mice with poly(I:C) together with D-galactosamine (D-GalN). D-
GalN sensitises the mice to the lethal effects of poly(I:C) injection via the 
overproduction of proinflammatory cytokine TNF in the liver (Dejager and Libert, 
2008). Interestingly, as shown in Figure III-3, Dok3-deficient mice were more 
resistant to poly(I:C)-induced sepsis as opposed to its wildtype control mice that 
readily succumbed to death after 8 hours from injection. Since this in vivo model is a 
result of excessive TNFα and other inflammatory cytokine production the data 
suggests that Dok3 unexpectedly mediate a positive regulatory role in TLR3 
signalling. This is in contrast to its other family member proteins including Dok1 and 
Dok2 that played an inhibitory role in LPS signalling (Shinohara et al., 2005). As 
Dok3 mice were more resistant to sepsis in our in vivo animal model, it may indicate 
that the inflammatory cytokines that were produced upon TLR3 signalling were 
perturbed by Dok3 deficiency.  
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Figure III-3 Dok3-deficient mice are more resistant to poly(I:C)-induced septic shock.  
Wildtype (Black line) and Dok3
-/-
 mice (Red line) were injected with 12.5 g poly(I:C) and 20 mg of 
D-GalN. The dose of poly(I:C) was calculated per 20 g of body mass. Survival of mice was monitored 
for over 24h. Statistical significance was established by paired student‟s t test, *p<0.05. 
 
To test this hypothesis, we sought to measure the proinflammatory cytokines that are 
known to be produced upon poly(I:C) stimulation of wildtype and Dok3-deficient 
macrophages. We performed both ELISA and intracellular cytokine staining (ICS) 
using flow cytometry (data not shown).  As shown in Figure III-4, the production of 
proinflammatory cytokines including IL-6, IL-12 and TNF in TLR3-stimulated 
macrophages were significantly reduced in the absence of Dok3. As controls, these 
analyses were performed alongside with TRIF and TLR3-deficient macrophages and 
the data indicated that Dok3-deficency exhibited the same phenotype as TRIF and 
TLR3-deficiency and suggest that Dok3 participates in a linear signal transduction 
pathway initiating from the activated receptor. 
 
 
Figure III-4 Dok3 positively regulate cytokine production in poly(I:C)-stimulated macrophages.  
Wildtype (black columns) and Dok3
-/-
 (white columns), TLR3
-/- 
(horizontal shaded columns) and TRIF
-
/- 
(vertical shaded columns) macrophages were untreated or treated with 50 g/ml poly(I:C) for 6h and 
their secretion of IL-6, IL-12p40 and TNF quantified via ELISA using known standards. Statistical 
significance was established by paired student‟s t test, *p<0.05. Figures shown are representative of at 
least 3 independent experiments. 
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3.4 Dok3 is involved in TLR3-dependent IFNβ gene induction and IFN-
dependent gene response 
TLR3 is known for its antiviral role in innate immunity. It primarily achieves its anti-
viral effects via the production of IFNβ, a type 1 IFN. Engagement of dsRNA by 
TLR3 in the endosome allows signalling to IFNβ. As such, we asked if Dok3-
deficiency would affect TLR3 induced IFNβ production. To this end, we stimulated 
wildtype and Dok3-deficient macrophages with poly(I:C) and assayed for IFNβ gene 
induction using quantitative real-time RT-PCR. We showed here in Figure III-5 that 
while we were able to readily detect IFNβ gene upregulation in wildtype macrophages 
stimulated with poly(I:C) for 2 hours, the IFNβ gene expression was largely defective 
in poly(I:C)-stimulated Dok3-deficient macrophages, similar to poly(I:C)-stimulated 
TRIF-deficient macrophages. The production of IFNβ, a hallmark cytokine of 
antiviral immune response, is amplified by its autocrine feed-forward loop of binding 
to its own receptor (Ihle et al., 1997). The signal transduction pathways emanating 
from either the TLR or IFN/β receptor lead to the activation of the IRF3 
transcription factor that in turn induces a specific set of genes expression. These genes 
are termed the IRF3-dependent gene response. One of the genes induced is RANTES 
(Regulated on Activation Normal T cell Expressed and Secreted). RANTES is known 
to be a chemokine important in the recruitment of neutrophils at the site of 
inflammation in an on-going viral infection (Rojas-Ramos et al., 2003). Given the fact 
that IFNβ gene induction is defective arising from Dok3 deficiency in TLR3 
signalling, it is possible that other gene inductions may be abrogated. We then 
investigated if Dok3 is required for RANTES gene induction following TLR3 
stimulation. As shown in Figure III-6, we were able to detect RANTES gene 
induction in TLR3-stimulated wildtype macrophages but RANTES induction was 
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defective in TLR3-stimulated Dok3
-/-
 macrophages. These results suggest that Dok3 
plays a role in signalling to IFNβ and RANTES production via TLR3.  
 
Figure III-5 Dok3 regulates IFN gene induction in poly(I:C)-stimulated macrophages.  
Real-time qPCR analysis of IFN mRNA expression in wildtype (black columns), Dok3-/- (white 
columns) and TRIF
-/-
 (shaded columns) macrophages stimulated with 50 g/ml poly(I:C) for 2h. The 
amount of IFN mRNA expression was normalized to that of actin mRNA. Figures shown are 
representative of at least 3 independent experiments. 
3.5 Dok3 is required for TLR3-mediated activation of PI3K but not MAPK 
and NFB 
Multiple signalling pathways are known to be activated downstream of TLR3 
engagement. These include the MAPKs, PI3K and NFB (Schroder and Bowie, 
2005). These signal transduction pathways culminate in the activation of various 
transcription factors which lead to specific gene expression and translation of required 
proteins that are critical in co-ordinating the magnitude of host innate immune 
response. For example, the MAPKs will activate the AP-1 transcription factors that 
are known for their roles in the production of proinflammatory cytokines (Ameyar et 
al., 2003). The NFB signalling pathway on the other hand activates the p65/p50 
heterodimer transcription factor that is also known to induce inflammatory 
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components (such as TNFα and COX2) which acts as a co-factor on the IFN 
enhanceosome to induce IFNβ.  
The PI3K pathway activated downstream of TLR3 was recently defined as a detour 
signalling pathway downstream of TLR3 that does not involve TRIF but nonetheless 
also culminates in the activation of TBK1 that is a direct kinase of IRF3 activation 
(Fitzgerald et al., 2003a; Hiscott, 2004). IRF3 is predominantly activated via the 
TRIF-TBK1 signalling axis to induce IFNβ production (Doyle et al., 2002). We have 
shown earlier that the production of cytokines such as IL-6, IL-12, TNF and IFNβ 
was defective due to Dok3 deficiency upon TLR3 stimulation in macrophages. As 
such, we asked if the major signal transduction pathways activated downstream of 
TLR3 would be affected in the absence of Dok3. We show here in Figure III-7 that 
when wildtype macrophages were stimulated with poly(I:C), it readily leads to the 
phosphorylation of MAPKs including ERK, JNK and p38. However, Dok3 deficiency 
did not lead to any drastic effect on MAPK activation as the phosphorylation of ERK 
and p38 were comparable and JNK was only slightly reduced in Dok3-deficient 
macrophages compared to wildtype control upon poly(I:C) stimulation. We next 
measured the activation of NFB in TLR3 signalling by examining IB degradation. 
As shown in Figure III-8, the kinetics of IB degradation upon poly(I:C) stimulation 
were also comparable between wildtype and Dok3-deficient macrophages, suggesting 
that Dok3 does not play a role in TLR3-mediated NFB signalling. 
 




Figure III-6 Dok3 regulates RANTES gene induction in poly(I:C)-stimulated macrophages.  
Real-time qPCR analysis of RANTES mRNA expression in wildtype (black columns) and Dok3
-/-
 
(white columns) macrophages stimulated with 50 g/ml poly(I:C) for 2h. The amount of RANTES 
mRNA expression was normalized to that of actin mRNA. Figures shown are representative of at least 
3 independent experiments. 
 





 macrophages were stimulated with 50 g/ml poly(I:C) for the indicated 
timepoints. Cells were lysed and analysed by immunoblotting with phospho-antibodies to (A) ERK, 
(B) JNK and (C) p38. Loading of equal amount of lysates were verified by immunoblotting with 








Figure III-8 Normal NFB activation in poly(I:C)-stimulated Dok3-/- macrophages.  
Normal IB degradation in poly(I:C)-stimulated Dok3-/- macrophages. Wildtype and Dok3-/- 
macrophages were simulated for various times with 50 g/ml poly(I:C) and examined by Western blot 
analysis for the degradation of IB. Anti-p38 blot was included as control for equal loading of cell 
lysates.  
 
As we have shown that Dok3 is redundant in TLR3- mediated MAPK and NFB 
pathway, we next investigated if Dok3 would play a role in PI3K signalling following 
TLR3 activation. We stimulated wildtype and Dok3-deficient macrophages with 
poly(I:C) and assayed for the phosphorylation of AKT at two activation residues, 
threonine 308 and serine 473 residue. The activation of AKT at these two acceptor 
sites was indicative of substrate activity for PI3K kinase activity following 
recruitment to TLR3 when the receptor is phosphorylated at tyrosine 759 residues 
(Sarkar et al., 2004). We show here in Figure III-9 that Dok3 deficiency impairs the 
phosphorylation of AKT and this suggests that Dok3 is required for PI3K signalling 
to activate IFNβ production in TLR3 signalling. 




Figure III-9 Impaired AKT pathway in poly(I:C)-stimulated Dok3
-/-
 macrophages.  
Wildtype and Dok3
-/-
 macrophages were stimulated with 50 g/ml poly(I:C) for the indicated 
timepoints. Cells were lysed and analysed by immunoblotting with phospho-antibodies to AKT (Serine 
473) (top panel) and AKT (Threonine 308) (bottom panel). Loading of equal amounts of lysates were 
verified by immunoblotting with antibodies to total AKT. Data shown are representative of two 
independent experiments. 




The IRF3 transcription factor belongs to a family of transcription factors that are 
involved in type 1 IFN production in an innate host immune response (Honda and 
Taniguchi, 2006). The notable anti-viral cytokine IFNβ can be activated by IRF 
binding to its promoter (Kim et al., 2000). These factors include IRF3 and IRF1 
(Honda and Taniguchi, 2006) and its activation is dependent on various upstream 
kinases. In TLR3 and TLR4 signalling, production of IFNβ is mainly triggered via 
TRIF which signals to TBK1 and subsequently activates IRF3. IRF3 normally exist as 
a monomer in the cytoplasm of the cells in a quiescent state and dimerises when it is 
active. This event coupled with phosphorylation of the transcription factor on serine 
396 residue allows the translocation of IRF3 to the nucleus to bind genomic DNA 
(Hiscott and Lin, 2005). Since IFNβ production is defective in TLR3-stimulated 





 macrophages we investigated if Dok3 is required for the activation of IRF3 
transcription factor. We first performed fractionation studies to divide the protein pool 
of macrophages from wildtype and Dok3-deficient mice into cytosolic and nuclear 
fractions after stimulation with LPS and poly(I:C). As shown in Figure III-10, we 
were not able to detect significant amounts of nuclear IRF3 protein in Dok3-deficient 
macrophages as compared to wildtype macrophages upon TLR3 and TLR4 
stimulation. This suggests that Dok3 deficiency impairs the translocation of IRF3 into 
the nucleus by TLR3 and TLR4 signalling which uses the TRIF adaptor protein for 
this signalling event. We further confirmed these findings by applying confocal 
microscopy to analyse the effect of IRF3 translocation following poly(I:C) 
stimulation. As depicted in Figure III-11, we detected the co-localization of IRF3 with 
DAPI, a nuclear marker in wildtype macrophages upon poly(I:C) stimulation. In 







 macrophages, similar to macrophages that 
were untreated, suggesting an impairment of IRF3 nuclear translocation as a result of 
Dok3 deficiency in TLR3 signalling. 
 








Nuclear extracts were prepared from wildtype and Dok3
-/-
 macrophages stimulated with poly(I:C) 
(upper panel) and LPS (lower panel) for 1 hr and examined for the presence of IRF3 by western blot 
analyses. The anti-HDAC1 blot was included as control for equal loading of nuclear extracts. The 
results shown were representative of 2 independent experiments. 
 
 














mice were treated with poly(I:C) for 1 hr and 
stained with IRF3 antibody and DAPI and imaged with confocal microscope for IRF3 translocation. 
The results shown were representative of 2 independent experiments. 
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3.7 Dok3 is critical for TRIF-dependent TBK1 and IRF3 phosphorylation 
Another prerequisite that is indicative of IRF3 activity is the phosphorylation of IRF3 
at serine 396 residue (Fitzgerald et al., 2003a). This event happens in the cytosol 
(Hiscott and Lin, 2005). The phosphorylation of IRF3 on serine 396 residue however 
depends on the presence of an active TBK1 as a study previously demonstrated that a 
defective or kinase-dead TBK1 is unable to phosphorylate IRF3 (McWhirter et al., 
2004). To determine whether phosphorylation of the TBK1-IRF3 signalling axis via 
TRIF to induce IFNβ production requires Dok3 in TLR3 and TLR4 signalling, we 
examined the activation of TBK1 on serine 172 residue as well as activation of IRF3 
on serine 396 residue. As shown in Figure III-12, when wildtype macrophages were 
treated with poly(I:C) and LPS in a time-dependent manner, it led to the robust 
phosphorylation of IRF3 on serine 396 residue. In contrast, we did not detect IRF3 
phosphorylation in Dok3-deficient macrophages treated in the same manner. We then 
investigated if the phosphorylation of TBK1 is affected downstream of TLR3 by the 
lack of Dok3. To this end, we immunoprecipitated TBK1 from TLR3-stimulated 
wildtype and Dok3
-/-
 macrophages and examined via Western Blotting, its 
phosphorylation at the serine 172 residue. We show here in  
Figure III-13, that although TBK1 activation at Serine 172 was detectable in TLR3-
stimulated wildtype macrophages, they were however impaired by Dok3 deficiency. 
Altogether, the current data indicates that Dok3 plays a non-redundant role in TLR3 
signalling to induce IFNβ production. The presence of Dok3 is also required for the 
activation of TBK1 which is necessary for IRF3 activity, including phosphorylation 
on its Serine 396 residue and subsequent nuclear translocation from the cytoplasm of 
the cell.  









 macrophages were stimulated with 50 g/ml poly(I:C) (upper panel) and 100 
ng/ml LPS (lower panel) for the indicated timepoints. Cells were lysed and analysed by 
immunoblotting with phospho-antibodies to IRF3 (Serine 396). Loading of equal amounts of lysates 






Figure III-13 Impaired TBK1 phosphorylation in poly(I:C)-stimulated  Dok3
-/-
 macrophages.  
Wildtype and Dok3
-/-
 macrophages were stimulated with 50 g/ml poly(I:C) for the indicated 
timepoints. TLR3-stimulated wildtype and Dok3
-/-
 lysates were immunoprecipitated with TBK1 and 
immunoblotted with phospho-antibodies to TBK1 Serine 172. Loading of equal amounts of lysates was 
verified by immunoblotting with antibodies to total TBK1. Data shown are representative of 2 
independent experiments. 
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3.8 Dok3 interacts with TRAF3 and TBK1 and is required for TBK1 binding 
to TRAF3 in TLR3 signalling 
A previous study demonstrated that the proper assembly of TRAF3 and TBK1 
complex formation is essential in LPS signalling to induce IFNβ (Gatot et al., 2007). 
It was also shown in several other studies that the binding of TBK1 to the TRIF 
adaptor protein upon activation requires TRAF3 and this binding enables downstream 
signalling to occur (Guo and Cheng, 2007; Hacker et al., 2006). As such, TRAF3 and 
TBK1 complex formation is deemed important prerequisites for signalling to IFNβ. 
Dok3 intrinsically functions as a adaptor protein in several receptor signalling studies, 
namely BCR and FcRIIb (Lemay et al., 2000). Hence we asked if Dok3 could also 
function as an adaptor to stabilize the association between TRAF3 and TBK1 in 
TLR3 signalling. To answer this question, we immunoprecipitated TRAF3 from 
poly(I:C)-stimulated macrophages and examined TBK1 association by western 
blotting. We can see here in Figure III-14, that whereas stable TBK1 and TRAF3 
complex formation was detected in TLR3-stimulated wildtype cells, the lack of Dok3 
protein appears to abolish this complex formation as they are undetectable in TLR3-
stimulated Dok3-deficent macrophages. This data from endogenous 
immunoprecipitation (IP) suggest that in primary macrophages Dok3 is required for 
the formation of the TBK1 and TRAF3 complex in TLR3 signalling. However we 
were unable to distinguish if the associations to TBK1 and TRAF3 occurred via direct 
interaction. Dok3 possesses an SH2-target motif domain containing tyrosine motif  
which is commonly known to mediate protein and protein interaction (Pawson and 
Gish, 1992). The above results prompted us to ask if Dok3 could interact with TRAF3 
and/or TBK1 directly. To address this we constructed Dok3, TBK1 and various TRAF 
family member plasmids tagged with HA or FLAG and tested the interaction of these 
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proteins in IP assays using a mammalian cell overexpression system, HEK293T. As 
shown in  
Figure III-15, Dok3 interacts directly with TRAF3. As a control, it did not bind 
specifically to TRAF2 or 6. We also showed here that Dok3 interacts directly with 
TBK1 in HEK293T cells ( 
Figure III-16). The findings that Dok3 interact with TBK1 (fig upper panel) and 
TRAF3 (fig lower panel) directly were also confirmed via confocal microscopy as the 
proteins exhibited co-localisation when overexpressed together in HEK293T cells 
(Figure III-17B).  
 
Figure III-14 Dok3 is required for TRAF3 association with TBK1 upon poly(I:C) stimulation. 
Wildtype and Dok3
-/-
 macrophages were stimulated with 50 g/ml poly(I:C) for 30 mins. Cells were 
immunoprecipitated with antibodies to TRAF3 and analysed for TBK1 binding or vice versa by 
western blot analysis. Loading of equal amount of lysates was verified by immunoblotting with 









Figure III-15 Dok3 interacts with TRAF3.  
Immunoblot analysis of HEK293T cells 24 hrs after co-transfection of haemagglutinin (HA)-tagged 
TRAF3 with FLAG-tagged Dok3, HA-tagged TRAF6 with FLAG-tagged Dok3 and HA-tagged 
TRAF2 with FLAG-tagged Dok3, followed by immunoprecipitation with anti-FLAG antibodies and 
immunoblot with anti-HA antibodies. Whole cell lysates (WCL), immunoblot analysis of total cell 





Figure III-16 Dok3 interacts with TBK1. 
Immunoblot analysis of HEK293T cells 24 hrs after co-transfection of haemagglutinin (HA)-tagged 
TRAF3 with FLAG-tagged Dok3 and HA-tagged TBK1 with FLAG-tagged Dok3 followed by 
immunoprecipitation with anti-FLAG antibodies and immunoblot with anti-HA antibodies.. WCL, 
immunoblot analysis of total cell lysates with anti-HA and anti-FLAG. Data are from one experiment 
representative of 3 independent experiments. 
 




Figure III-17 Confocal images of Dok3 co-localisation with TBK1 and TRAF3.  
(A) HEK293T cells were transfected with Dok3-GFP and HA-c-Abl and immunofluorescence staining 
was performed using antibodies against HA-Alexa 546 goat anti-mouse as a positive control to 
demonstrate co-localisation. (B) HEK293T cells were transfected with Dok3-GFP and HA-TBK1 or 
HA-TRAF3 and immunofluorescence staining was performed using antibodies against HA-Alexa 546 
goat anti-mouse. Confocal images were taken using and Olympus confocal microscope to determine 
co-localisation. Images shown are representative of two independent experiments. 
3.9 Dok3 binds TRAF3 and TBK1 via SH2 target motif 
Dok3 protein structure is divided into mainly the N-terminal PH domain, an 
intermediary PTB domain and the C-terminal SH2 target motif containing tyrosine 
motifs (Lemay et al., 2000). As we showed Dok3 interacted with TBK1 and TRAF3 
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directly, we were interested in elucidating the domains of Dok3 that bind to TBK1 
and TRAF3, thus allowing an in-depth understanding of the molecular mechanisms 
that mediate the signal transduction events leading to IFNβ production in TLR3 
signalling. To map the binding site of Dok3 to TBK1 and TRAF3, we prepared 
truncated versions of Dok3 and conducted pull-down assays with TBK1 and TRAF3 
(Figure III-18). As showed in Figure III-19, we observed that Dok3 interacts with 
TRAF3 via the SH2 target motif. The interaction between Dok3 and TBK1 also 
requires the SH2 target motif (Figure III-20). 
 
 
Figure III-18 Pictogram depicting HA or FLAG-tagged Dok3 wildtype (WT) and truncated 
mutant Dok3. 
Dok3 full length protein (WT) or mutants harbouring various combinations of the PH (yellow), PTB 
(red) or tyrosine-rich carboxyl-terminal (blue) domains (D1 to D5). Numbers on the right indicate total 
number of Dok3 amino acid residues. 




Figure III-19 Dok 3 binds TRAF3 via SH2-target motif domain.  
HEK293T cells were transfected with HA-tagged TRAF3 together with FLAG-tagged Dok3 full length 
or various mutants and cell lysates were immunoprecipitated with anti-HA antibody and 
immunoblotted with anti-FLAG antibodies. WCL were also included to ensure expression of the 
various transfected genes constructs. Data shown are representative of more than 2 independent 
experiments. 





Figure III-20 Dok3 binds TBK1 via its SH2-target motif domain.  
HEK293T cells were transfected with HA-tagged TBK1 together with FLAG-tagged Dok3 full length 
or various mutants and cell lysates were immunoprecipitated with anti-HA antibody and 
immunoblotted with anti-FLAG antibodies. WCL were also included to ensure expression of the 
various transfected genes constructs. Data shown are representative of more than 2 independent 
experiments. 
3.10 Dok3 does not bind to TRIF adaptor protein  
Since Dok3 binds to TBK1 and TRAF3 directly, we next investigated if Dok3 can 
interact with the TRIF adaptor protein, which is the immediate signalling protein 
downstream of TLR3 (Oshiumi et al., 2003). We performed immunoprecipitation 
experiments with HA/FLAG-tagged Dok3, TRIF and TRAF3 in overexpressed 
HEK293T cell lysates and as shown here in Figure III-21, in the positive control 
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lanes, TRAF3 can bind to TRIF directly. However, Dok3 could not be 
immunoprecipitated with TRIF and this suggests that Dok3 does not interact with 




Figure III-21 Dok3 does not bind to TRIF adaptor protein.  
HEK293T cells were transfected with HA-tagged TRAF3 and HA-tagged Dok3 together with FLAG-
tagged TRIF and cell lysates were immunoprecipitated with anti-FLAG antibody and immunoblotted 
with anti-HA antibodies. WCL were also included to ensure expression of the various transfected genes 
constructs. Data shown are representative of more than 2 independent experiments. 
3.11 BTK phosphorylate Dok3 for optimal IFNβ production  
We demonstrated earlier in this chapter that Dok3 undergoes tyrosine phosphorylation 
upon poly(I:C) stimulation (Figure III-1). Tyrosine phosphorylation of Dok3 is not 
only indicative of Dok3 activation status but is also known for its adaptor function 
(Lemay et al., 2000). The identity of the tyrosine kinase that could possibly 
phosphorylate Dok3 in TLR3 signalling is unknown and is of interest. One such 
tyrosine kinase recently shown to be involved in TLR3 signalling is BTK but not Lyn 
and it was shown that BTK directly phosphorylated the receptor to initiate TLR3 
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activation (Lee et al., 2012). We then asked if BTK could be the tyrosine kinase that 
phosphorylates Dok3 in TLR3 signalling. We first checked if Dok3 can interact with 
BTK as these two proteins were known to be associated with each other in BCR 
signalling (Stork et al., 2007). To this end, we immunoprecipitated HA and/or FLAG-
tagged Dok3 and BTK in overexpressed HEK293T lysates and showed here in Figure 
III-22 that Dok3 interacts with BTK directly. Next, we asked if BTK can 
phosphorylate Dok3. We transfected HA and/or FLAG-tagged BTK and Dok3 into 
RAW 264.7 macrophage cell lines that endogenously expresses TLR3 and stimulate 
these cells with poly(I:C). Further examination of Dok3 tyrosine phosphorylation 
from immunoprecipitated RAW cell lysates by phospho-tyrosine antibodies (4G10) 
showed (Figure III-23) that co-expression of both BTK and Dok3 resulted in 
detectable Dok3 tyrosine phosphorylation upon TLR3 stimulation. These results 
verify that BTK is the tyrosine kinase that phosphorylates Dok3 in TLR3 signalling. 
We next investigated if Dok3 may be a substrate for BTK‟s enzymatic activity. We 
transfected FLAG-tagged Dok3 together with HA-tagged BTK or BTK  mutants 
plasmids including point mutations that lead to constitutive (E41K) kinase activity or 
point mutations that abolished (K430R) BTK kinase activity into HEK293T cells and 
examined the phosphorylation of ectopically expressed Dok3. We showed here in 
Figure III-24 (A) that Dok3 phosphorylation as indicated by 4G10 staining was 
visibly detectable by co-expression with BTK or its constitutive form but not by the 
kinase-dead BTK. In addition, Dok3‟s phosphorylation in TLR3-stimulated 
macrophages was defective by Btk‟s deficiency (Figure III-21 B). These results 
indicate that Dok3 is a substrate of BTK in TLR3 signalling leading to the activation 
of IRF3 and production of IFNβ. 




Figure III-22 Dok3 interacts with BTK. 
HEK293T cells were transfected with HA-tagged BTK together with FLAG-tagged Dok3 and cell 
lysates were immunoprecipitated with anti-FLAG antibody and immunoblotted with anti-HA 
antibodies. WCL were also included to ensure expression of the various transfected genes constructs. 
Data shown are representative of more than 2 independent experiments 
 
Figure III-23 BTK phosphorylates Dok3 in RAW264.7 cells. 
RAW264.7 macrophage cell lines were transfected with HA-tagged BTK together with FLAG-tagged 
Dok3 and cell were stimulated with or without poly(I:C) and immunoprecipitated with anti-FLAG 
antibody and immunoblotted with 4G10 antibodies. WCL were also included to ensure expression of 
the various transfected gene constructs. Data shown are representative of more than 2 independent 
experiments. 




Figure III-24 BTK kinase activity is required for Dok3 phosphorylation.  
(A) HEK293T cells were non-transfected or transfected with FLAG-tagged Dok3 together with HA-
tagged BTK, constitutively-active BTK (E41K) or kinase-dead BTK (K430R). Cell lysates were 
immunoprecipitated with anti-FLAG antibody and immunoblotted with anti-phospho-tyrosine (4G10) 
or anti-FLAG antibodies. WCL were also included to ensure expression of the various transfected 
genes constructs.  (B) Wildtype and btk 
-/-
 macrophages were stimulated with 50 g/ml poly(I:C) for 60 
mins. Cells were immunoprecipitated with antibodies to Dok3 and control IgG antibodies and analysed 
for Dok3 phosphorylation by pTyr antibodies. Loading of equal amount of lysates was verified by 
immunoblotting with antibodies to total Dok3. Data shown are representative of more than 3 
independent experiments. 
3.12 Dok3 acts in concert with BTK and TBK1 to induce IFNβ promoter 
Using biochemical approaches, we have shown that Dok3 interacts with TBK1, 
TRAF3 and BTK but not TRIF in TLR3 signalling. To independently confirm that 
Dok3 positively regulates IFNβ production we investigated the effect of Dok3 
interacting with BTK and TBK1 in cellular responses induced by TLR3. To achieve 
this we overexpressed these proteins and measured the physiological outcomes using 
IFNβ-luciferase promoter assays. As demonstrated in Figure III-25, Dok3 protein 
expression alone does not drive IFNβ promoter activity whereas TBK1 protein 
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expression can induce some levels of basal IFNβ promoter activity. Indeed, when 
Dok3 was co-expressed with TBK1, there was a higher induction of IFNβ promoter 
activity as compared to the expression of single proteins. We found from this data that 
Dok3 and TBK1 could cooperatively promote IFNβ activity in the luciferase promoter 
assay. Previously, we have demonstrated that the interaction of TBK1 and Dok3 is 
mediated via the Dok3 SH2-target motif. Hence we checked if this protein domain 
responsible for Dok3 interaction with TBK1 is required to promote IFNβ activity.  
 
To this end, we expressed TBK1 and Dok3 singly as well as co-expressed TBK1 with 
wildtype Dok3 or its truncated mutants (lacking PH domain (D4), lacking in SH2 
target motif (D2) and containing only SH2 target motif (D5)) and examined their 
ability to promote IFNβ activity. As shown in Figure III-26, we found that Dok3 and 
TBK1 together induce higher levels of IFNβ promoter activity but this process 
requires the Dok3 SH2-target motif protein domain. Expression of the SH2 target 
motif protein domain of Dok3 (D5) is enough to synergise with TBK1 to induce IFNβ 
luciferase activity. Last but not least, we were interested to elucidate if there is an 
additive effect of promoting IFNβ activity under a triple expression of Dok3 together 
with TBK1 and BTK. As shown in Figure III-27, the triple expression of three 
proteins drive IFNβ promoter activity much further than when compared to 
expressing TBK1 or TBK1 together with Dok3. These findings together affirm the 
role of Dok3 adaptor protein in the positive regulation of IFNβ production. 




Figure III-25 Dok3 synergizes with TBK1 to induce IFNβ promoter activity.  
HEK293T cells were transfected with Dok3 (20 to 100ng) and/or TBK1 (100ng)-encoding plasmids 
together with reporter (IFNβ luciferase) and control plasmids (Renilla luciferase) into 48-well plates. 
After 24 hrs the activation of reporter was measured. Data shown is representative of 5 independent 
experiments. 
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Figure III-26 The SH2-target motif of Dok3 is required for binding to TBK1 to induce IFNβ 
promoter activity.  
HEK293T cells were transfected with either Dok3 (100ng) or various Dok3 mutants lacking either PH 
(D4), SH2-target motif (D2) or containing only SH2- target motif (D5) (all 100ng) and/or TBK1 
(100ng)-encoding plasmids together with reporter (IFNβ luciferase) and control plasmids (Renilla 
luciferase) into 48-well plates. After 24 hrs, the activation of reporter was measured. Data shown is 
representative of 3 independent experiments.  
 
 
Figure III-27 BTK acts in concert with Dok3 and TBK1 to drive IFNβ gene expression.  
HEK293T cells were transfected with Dok3 (100ng), TBK1 (100ng) and/or BTK (100ng)-encoding 
plasmids together with reporter (IFNβ luciferase) and control plasmids (Renilla luciferase) into 48-well 
plates. After 24 hrs, the activation of reporter was measured. Data shown is representative of 3 
independent experiments. 
3.13 Dok3 played a role in intracellular RIG-1 pathway and is required for 
clearance of influenza virus 
Various studies have demonstrated that poly(I:C) stimulation of cells can be 
recognized not only by endosomal bound TLRs such as TLR3 but also by RLRs that 
can activate the antiviral response via the RIG-I/MDAS pathway (Kato et al., 2006; 
Kato et al., 2008). We have demonstrated definitively that poly(I:C) stimulation of 
Dok3-deficient macrophages led to defective production of IFNβ as compared to 
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wildtype control cells (Figure III-5). Experimentally, the defect was observed with the 
addition of poly(I:C) into the culture media to stimulate the cells. It is established in a 
number of publication that this method of addition of the poly(I:C) ligand stimulates 
the cell via the TLR3 pathway as the ligand is taken up via endocytosis with the 
poly(I:C) or eventually engaging TLR3 once being trafficked to the endosome 
(Vercammen et al., 2008). Therefore, in order for poly(I:C) to activate the RIG-
I/MDA5 pathway of antiviral response optimally, the poly(I:C) ligand has to be 
transfected or introduced directly into the cytosol of host cells by various transfection 
reagents including lipofectamine or LyoVec (Kawai and Akira, 2007) or by 
electroporation (Busillo et al., 2011). Since TRAF3/TBK1 complex is also involved 
in RIG-I pathways and we showed that Dok3 is important for TRAF3/TBK1 complex 
formation, we hypothesize that Dok3 might also participate in RLR signalling. To 
address this hypothesis, we examined IFNβ gene expression in wildtype and Dok3-
deficient macrophages that were stimulated with poly(I:C) packaged in the 
transfectant reagent LyoVec that allowed the introduction of the dsRNA mimetic 
directly into the cytoplasm of host cells to activate the RLR-dependent RIG-I/MDA5 
signalling pathway. We showed here in Figure III-28 that whereas IFNβ gene 
expression was detectable in wildtype cells upon transfecting poly(I:C), it was 
however defective in transfected Dok3 cells
-/-
. This data indicated that Dok3 is not 
only required for TLR3 signalling but also suggest that Dok3 may play a role in RLR 
signalling. We next asked if Dok3 is phosphorylated by transfected poly(I:C) as 
indicated by its involvement by RLR signalling. As seen in Figure III-29, tyrosine 
phosphorylation of Dok3 was clearly detectable 3 hours after stimulation by 
transfected poly(I:C) in wildtype macrophages. The RLR pathway activates antiviral 
responses via the RIG-I/MDA5 pathway that signals through IPS-1 adaptor protein. 
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This subsequently leads to the activation of TBK1 that phosphorylates IRF3 for 
inducing IFNβ cytokine production (Kawai et al., 2005). We next examined if 
phosphorylation of IRF3 is affected by Dok3 deficiency in macrophages transfected 
with poly(I:C). We show here in Figure III-30 that when wildtype macrophages are 
stimulated with transfected poly(I:C), it leads to the phosphorylation of IRF3 after 6 
hours of post-stimulation. However phosphorylation of IRF3 was absent when Dok3-
deficient macrophages were treated in a similar manner. Taken together our data here 
also suggest that Dok3 could participate in RLR signalling in addition to our 
demonstration that Dok3 is involved in TLR3 signalling. 
 
It is also known that TLR3 and RLRs are key antiviral immune pathways against 
infectious viral diseases such as influenza and dengue (Kawai and Akira, 2007). 
Intracellular replication of virus within the host cells generate dsRNA intermediates 
that are known to be recognised by TLR3 and RLRs (Pauli et al., 2008; Tsai et al., 
2009). The question then is whether there is a physiological role for Dok3 in 
combating virus infections. To this end, we employed an influenza virus infection 
model to decipher if Dok3 played a role in limiting virus infection and replication 
with the notion that Dok3 is required for optimal antiviral IFNβ production. To test 
whether reduced production of IFNβ by TLR3 and RLR-stimulated Dok3-/- 
macrophages would compromise antiviral responses, we infected wildtype and Dok3-
deficient macrophages with influenza viruses. As shown in Figure III-31 A, 
quantitative real-time PCR analyses indicated that Dok3
-/-
 macrophages were 
defective in the production of IFNβ upon influenza virus infection and concomitant 
with this defect, the replication of the influenza virus as measured by the presence of 
viral RNA, was much more pronounced in the mutant compared to wildtype 
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macrophages (Figure III-31 B). The data altogether demonstrated the importance of 
Dok3 in antiviral TLR3 and RLR signalling. 
 
Figure III-28 Dok3 regulates IFN gene induction in transfected poly(I:C)-stimulated 
macrophages.  
Real-time qPCR analysis of IFN mRNA expression in wildtype (black columns), Dok3-/- (white 
columns) macrophages stimulated with 10 g/ml poly(I:C)/LyoVec for 6 hr. The amount of IFN 
mRNA expression was normalized to that of actin mRNA. Figures shown are representative of at least 
2 independent experiments.  
 
 
Figure III-29 Dok3 is phosphorylated in macrophages upon transfected poly(I:C) stimulation.  
BMM were stimulated for 3 hrs as indicated with 10 g/ml poly(I:C)/LyoVec and subsequently lysed. 
Dok3 was immunoprecipitated and probed with anti-phospho-tyrosine (pY) or anti-Dok3 antibodies. 
Figure shown is representative of two independent experiments. 
 










 macrophages were stimulated with 10 g/ml poly(I:C)/LyoVec for 6 hr. Cells 
were lysed and analysed by immunoblotting with phospho-antibodies to IRF3 (Serine 396). Loading of 
equal amounts of lysates was verified by immunoblotting with antibodies to total IRF3. Data shown are 
representative of 2 independent experiments. 




Figure III-31  Dok3 is required for inhibition of influenza A virus replication.  
WT and Dok3
-/-
 macrophages were infected with dengue virus and at 72 hrs post-infection assayed for 
IFN- mRNA (A) and presence of influenza A virus RNA (B) via semi-quantitative RT-PCR.  The 
actin RT-PCR served as control for loading of templates. . Statistical significance was established by 
paired student‟s t test, *p<0.05. Data shown are representative of 2 independent experiments. 
 
 




Several studies have implicated the role of Dok family members in TLR signalling. 
More recently, Dok3 was shown to be important in lung carcinoma development 
(Berger et al., 2010). The role of Dok3 in TLR pathway however is elusive. In this 
chapter study, we utilised Dok3
-/-
 mice to discern the physiological role of Dok3 in 
TLR3 signalling. In our initial screening experiments of assaying inflammatory 
cytokine production via ELISA using a panel of TLR ligands against wildtype and 
Dok3-deficient macrophages, we found no observable differences for cells that were 
stimulated with the TLR ligand that signals through MyD88, for example CpG, ligand 
for TLR9 and R837, ligand for TLR7 and TLR8 (data not shown), with the exception 
of poly(I:C), ligand for TLR3 and LPS, ligand for TLR4 (Figure III-4 and Figure 
IV-2). The commonality between TLR3 and TLR4 lies in the usage of TRIF adaptor 
protein. It has been shown interestingly that in LPS signalling via TLR4, the cytokine 
production predominantly occurs via TRIF and not MyD88 (Yamamoto et al., 2003). 
This enabled us to exclude the possibility that Dok3 has a functional relevance in 
signalling through MyD88 and prompted us to examine in greater detail its role in 
TRIF-dependent signalling mediated via TLR3 and TLR4. We primarily used naked 
poly(I:C) as a TLR3 ligand in our assays. The poly(I:C) is a synthetic analogue and 
mimics viral dsRNA that is exposed to host immune cells and trigger TLR3 
specifically in the endosome. 
 
We report here that Dok3 undergoes tyrosine phosphorylation upon poly(I:C) 
stimulation in macrophages. This indicates that Dok3 is “activated” during TLR3 
signalling. More importantly, we also showed that the induction of Dok3 
phosphorylation requires the presence of TRIF. We went on to delineate the 
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physiological aspects of Dok3‟s role in TLR3 signalling. Many studies have 
suggested an inhibitory role of Dok family members (for example Dok1 and Dok2) in 
TLR signalling (Shinohara et al., 2005). In this current study however, we report an 
unexpected and surprising discovery that Dok3 mediates a positive regulatory role in 
TLR3 signalling. The poly(I:C)-induced sepsis model showed that mutant mice were 
more resistant to poly(I:C)-induced sepsis compared with wildtype control mice. This 
in-vivo result is consistent with our in-vitro ELISA data that indicate that the 
proinflammatory cytokines production upon TLR3 signalling was defective in Dok3
-/-
 
cells and mice. 
 
We have examined the different major signalling pathways that are known to be 
activated downstream of TLR3 activation. These include PI3K, MAPK, NFB and 
IRF3 (Schroder and Bowie, 2005). IFNβ, a type 1 IFN, is an important anti-viral 
cytokine against viral invasion. The optimal production of this cytokine is known to 
require the co-ordination of various transcription factors including AP-1, NFB and 
IRF3 binding to the IFNβ promoter region (PRDI-IV) known as the IFNβ 
enhanceosome (Kim et al., 2000). We found that Dok3 is dispensable for MAPK and 
NFB signalling downstream of TLR3 and this suggests the possibility of other 
proteins or related family members compensating for this specific role. Dok3 however 
is required for signalling to IRF3, the key transcription factor for inducing IFNβ as 
evident by several of our findings. We also discovered that Dok3 is important for 
activating the PI3K-AKT pathway to TBK1 and TRIF-mediated TBK1 signalling. 
Signalling via these two pathways from TLR3 eventually converges upon TBK1 
which is an essential kinase that phosphorylates and activates IRF3 to allow nuclear 
translocation and DNA binding to allow antiviral gene expression. 




In elucidating the molecular mechanism of Dok3‟s action in TLR3 signalling we 
found that Dok3 acts at the level of stabilizing TBK1 and TRAF3 complex formation 
to signal to IFNβ by directly interacting with these proteins. This is consistent with 
the intrinsic role of Dok3 behaviour as an adaptor protein. We further delineate and 
dissect the domain of Dok3 that mediate the interaction and specifically identify the 
SH2-target motif and/or PTB domain for binding to TBK1 and TRAF3, respectively. 
We also report that signalling via PI3K-AKT is defective due to the lack of Dok3. 
This signalling pathway downstream of the receptor, TLR3, was identified as a detour 
as opposed to the mainstream signalling pathway that is dependent on TRIF (Hiscott, 
2004). The phosphorylation of TLR3 on tyrosine 759 was found to be important in the 
recruitment of PI3K in mutagenesis studies (Sarkar et al., 2004). More recently, this 
pathway, otherwise termed TRIF-independent branch of TLR3 signalling, was 
reported to be essential in other cellular activities including cell migration and 
adhesion (Yamashita et al., 2012b). Attempts made to identity the tyrosine kinase 
critical for the phosphorylation of TLR3 at tyrosine 759 residue led to the 
identification of BTK and c-SRC as important mediators of TLR3 signalling (Johnsen 
et al., 2006; Lee et al., 2012). As BTK, an SRC-family member, Lyn and Dok3 were 
largely well-characterised in BCR signalling and exhibiting mutually non-exclusive 
roles in B cell development, it is useful to extrapolate their roles for TLR3 signalling. 
One possible scenario is that upon TLR3 engagement by dsRNA, BTK undergoes 
SRC-dependent activation and phosphorylates TLR3 to initiate signalling events. It 
has been demonstrated that BTK binds TRIF (Liu et al., 2011) and Dok3 interacts 
with BTK (Figure III-32). Our work separately indicated that Dok3 undergoes 
tyrosine phosphorylation upon TLR3 activation and we thought that BTK may be the 
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kinase responsible. Indeed we proved that this is the case. This then points to Dok3 
possibly exerting an adaptor function to bridge TBK1, TRAF3 to amplify the 
signalling events to IRF3, which is critical for the induction of IFNβ (Figure III-32). 
Moreover the absence of Dok3, i.e. loss of adaptor function results in impairment in 
the PI3K-AKT pathway as observed in TLR3-stimulated Dok3
-/-
 macrophages as this 
pathway may be heavily dependent on BTK-Dok3 activity. In conclusion, these 
results highlight the importance of adaptor function in the context of Dok3 bridging 
and or stabilizing other proteins (i.e., BTK and/or TBK1 and TRAF3) in a 
signalosome formation in TLR3 signalling. 
 




Figure III-32 A working model for Dok3’s role in TLR3 signalling.  
Upon activation by dsRNA, it leads to the dimerization and activation of TLR3. This likely result in the 
recruitment of TRIF and BTK of which BTK is required to fully phosphorylate TLR3 at tyrosine 759 
residue. BTK then interacts with and phosphorylate Dok3. Dok3 is then required to interact with TBK1 
and TRAF3 and mediates the interaction of TBK1/TRAF3 to TRIF for TRIF-dependent signalling 
pathways downstream of TLR3 including TBK1-mediated IRF3 activation of which is required for an 
effective assembly of a functional -interferon enhanceosome to secrete IFN, a critical type I IFN for 
an anti-viral immune response.   
 




CHAPTER IV. ROLE OF DOK3 IN TLR4 SIGNALLING IN 
MACROPHAGES 
 




Toll-like receptors are germ-line encoded pattern recognition receptors (PRR) that 
detect infectious agents collectively referred to as pathogen associated molecular 
pattern (PAMP).  For example, lipopolysaccharide (LPS) is a Gram-negative bacteria 
cell wall component that upon contact with TLR4 can induce the intracellular 
signalling cascade known as TLR4 signalling. TLR dimerization upon ligand 
presentation allows the binding of cytoplasmic adaptor molecules such as MyD88, 
MyD88 adaptor-like MAL, TIRAP and TRIF. Almost all TLRs signal via the 
universal adaptor MyD88 with the exception of TLR3 and TLR4.  In the case of 
TLR4 it utilizes MyD88 and TRIF to trigger the respective pathways. Activation of 
MyD88 recruits and phosphorylates two kinases (IRAK1 and 4). This is followed by 
the activation of the cytoplasmic adaptor TRAF6. Once TRAF6 forms a complex with 
Ubc13/Uev1 E2, it then functions as an ubiquitin ligase to polyubiquitinate TAK1. 
Activated TAK1 then upregulates the transcription factor NFκB through the IKK 
complex and the MAPK family. TRIF-dependent pathway also activates both the 
NFκB and the MAPK family but the IKK complex is activated via recruitment of 
RIP1 (Meylan et al., 2004). 
 
The quintessential function of the abovementioned signalling cascades are to activate 
the necessary gene transcription to produce proinflammatory cytokines such as TNF 
which are necessary to respond to pathogenic invasion.  Whilst TLR activation is 
necessary to control dissemination of the pathogen it is also portrayed as a double-
edged sword as sustained release of potent cytokines such as TNF can result in 
pathogenesis of autoimmune, chronic inflammation and septic shock. Therefore 
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various negative regulators exist to maintain homeostasis between appropriate and 
inappropriate immune responses. However not all is fully understood especially 
regarding the mechanistic function of known negative regulators.  
 
The family of proteins downstream of kinase (Dok) has been thought to play 
inhibitory functions in signalling transduction. They do not have enzymatic activities 
alone but are able to bring the necessary molecules to activate signal transduction. 
Therefore Dok is also referred to as the adaptor/docking proteins. The first member of 
the Dok family p62, was identified in the hematopoietic progenitors isolated from 
chronic myelogenous leukemia patients and was found to be highly phosphorylated 
by numerous cytoplasmic tyrosine kinases such as Lyn, SYK and BTK (Niki et al., 
2004). To date there are seven known proteins that represent the Dok family. 
However only Dok1 (p62), Dok2 (p56/Dok-R/FRIP) and Dok3 (Dok-L) are highly 
expressed in hematopoietic cells. The basic overall structure of Dok consists of 
homologues PH-domain at the N terminus followed by a PTB region and a variant 
carboxyl terminal containing a few potential tyrosine kinase sites (Mashima et al., 
2009).  
 
Dok1 and Dok2 are involved in the negative regulation of numerous immune cell 
signalling transductions such as BCR, CD2 receptor, Fc receptor and TLR4 
signalling. In 2005 a single knockout study carried out by Shinohara et al 
demonstrated that while Dok1 or Dok2 was not essential for organism growth, upon 
LPS challenge, mice underwent fatal septic shock. Peritoneal resident and bone 
marrow derived macrophages from single knockout mice showed elevated levels of 
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TNF and NO production when stimulated with LPS. However, the responses to 
stimulation with other TLR ligands were normal (Shinohara et al., 2005). 
 
Dok3 is also expressed in hematopoietic cells such as B lymphocyte, myeloid cells 
and macrophages but not T cells. Structurally, unlike Dok1 and Dok2, Dok3 does not 
contain the repeated YXXP motifs in the carboxyl tail containing the binding site to 
p120rasGAP. Instead Dok3 is phosphorylated at tyrosine 398 and 432 by SRC kinase, 
which allows the binding of Grb2. Physiological studies of Dok3 knockout mice 
revealed that Dok3 is not detrimental to the organism and B cell development. 
However these mice have elevated basal levels of the serum IgM and heightened 
humoral responses against T-cell independent antigens.  Moreover upon BCR 
engagement, B cells hyperproliferate with enhanced upregulation of MAP Kinase, 
NFκB pathway and raised level of calcium signalling. Ng et al suggested that Dok3 
negatively regulate BCR signalling via activation of SHIP-1 although the exact 
mechanistic role of Dok3 still remains unclear (Ng et al., 2007). Together with the 
evidence that Dok1 and Dok2 play negative roles in TLR4 signalling, it is likely that 
Dok3 may also be involved in the regulation of signalling downstream of Toll-like 
receptors.  
 
In chapter 3, we examined the role of Dok3 in TLR3 signalling and showed that it 
played a positive regulatory role in inducing IFNβ production through the TRIF-
dependent pathway. It is known that TLR4 also used TRIF adaptor proteins to signal 
to IFNβ (Fitzgerald et al., 2003b). In addition to TRIF, TLR4 also uses another 
adaptor protein known as TRAM (Fitzgerald et al., 2003b) but TRAM is not utilised 
by TLR3 for signalling. Since Dok3 is required for TLR3-mediated TRIF dependent 
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activation of IFNβ, it may be possible that Dok3 is also required by TLR4 in its 
signalling to IFNβ. To determine if there is a specific role for Dok3 in TLR4 
signalling in macrophages, we examined the effect of the absence of Dok3 in TLR4 
engagement, which is an innate anti-bacterial PPR that recognizes endotoxins. 
(Poltorak et al., 1998) 
4.2 Dok3 is phosphorylated upon TLR4 stimulation 
To determine if Dok3 is involved in TLR4 signalling in macrophages, we investigated 
if Dok3 undergoes tyrosine phosphorylation upon LPS stimulation. We treated 
wildtype macrophages with LPS that engages TLR4. As shown in Figure IV-1, Dok3 
undergoes tyrosine phosphorylation upon LPS stimulation. The tyrosine 
phosphorylation of Dok3 was however not observed in the untreated cells or at 0 
timepoint. This data indicated that Dok3 may be required for a regulatory role in 
TLR4 signalling. 
 
Figure IV-1 Dok3 is phosphorylated in macrophages upon LPS stimulation.  
BMM were stimulated for various times as indicated with 1 g/ml LPS and subsequently lysed. Dok3 
was immunoprecipitated and probed with anti-phospho-tyrosine (pY) or anti-Dok3 antibodies. Figure 
shown is representative of two independent experiments.  
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4.3 Dok3-deficient macrophages exhibit reduced IL-6 secretion but normal 
production of IL-12 and TNF upon TLR4 stimulation 
LPS stimulation is known to lead to the production of proinflammatory cytokines that 
are mediated via the usage of four adaptor systems (O'Neill et al., 2003). A previous 
study demonstrated that upon TLR4 signalling, proinflammatory cytokine production 
was dependent on the cooperation of TRIF and MyD88 (Yamamoto et al., 2003). As 
Dok3 is phosphorylated in macrophages upon LPS stimulation, we asked if Dok3 is 
required for the proinflammatory cytokine productions downstream of TLR4. We 
measured with ELISA and by ICS flow cytometry the production of IL-6, IL-12 and 
TNF in TLR4-stimulated wildtype and Dok3-deficient macrophages (data not 
shown). As shown in Figure IV-2, Dok3-deficient macrophages exhibited reduced IL-
6 secretion but normal production of IL-12 and TNF upon TLR4 stimulation. As 
controls, these analyses were performed alongside with TRIF and TLR3-deficient 
macrophages. Cytokine production was defective in TLR4-stimulated TRIF
-/-
 
macrophages but however was normal in TLR4-stimulated TLR3
-/-
 macrophages, 
consistent with previous reports (Yamamoto et al., 2003). The data indicated that 
Dok3 may play only a marginal role in TLR4 signalling where its absence resulted 
only in a defective IL-6 cytokine production upon LPS signalling. 
 




Figure IV-2 Dok3 positively regulate cytokine production in LPS-stimulated macrophages.  
Wildtype (black columns) and Dok3
-/-
 (white columns), TLR3
-/- 
(grey columns) and TRIF
-/- 
(shaded 
columns) macrophages were untreated or treated with 100 ng/ml LPS for 6 hrs and their secretion of 
IL-6, IL-12p40 and TNF quantified via ELISA using known standards. Statistical significance was 
established by paired student‟s t test, *p<0.05. Figures shown are representative of at least 3 
independent experiments.  
 
4.4 TLR4 stimulated Dok3-deficient macrophages result in reduced IFN 
Signaling through TLR4 is known to trigger IFNβ production via the TRIF-dependent 
signaling axis. We have demonstrated in chapter 3 that Dok3 is important for IFNβ 
production in the TRIF pathway downstream of TLR3. We next investigated if Dok3 
is also required to operate in the TRIF-dependent signaling axis downstream of TLR4, 
analogous to TLR3, in inducing IFNβ. We show here in Figure IV-3, that in contrast 
to TLR4-stimulated wildtype macrophages that can readily induce IFNβ production, 
this was impaired in TLR4-stimulated Dok3 and TRIF-deficient macrophages. These 
results indicated that Dok3 is required in both TLR3 and TLR4-mediated signaling to 
IFNβ. 





Figure IV-3 Dok3 regulates IFN gene induction in LPS-stimulated macrophages.  
Real-time qPCR analysis of IFN mRNA expression in wildtype (black columns), Dok3-/- (white 
columns) and TRIF
-/-
 (shaded columns) macrophages stimulated with 100 ng/ml LPS for 2 hr. The 
amount of IFN mRNA expression was normalized to that of actin mRNA. Figures shown are 
representative of at least 3 independent experiments.  
4.5 TLR4-stimulated Dok3-deficient macrophages exhibit normal MAPK and 
IκBα activation 
TLR4 signaling pathways are known to lead to MAPK and NFB activation, 
mediated largely by signaling through MyD88 (Yamamoto et al., 2003). Thus we 
investigated if Dok3 is required for these signal transduction pathways downstream of 
TLR4. We stimulated wildtype and Dok3-deficient macrophages with 100 ng/ml of 
LPS and assayed for MAPK activation by western blotting. These MAPKs include 
phosphorylation of ERK, JNK and p38 (Takeda and Akira, 2005). We show in Figure 
IV-4 that the phosphorylation of ERK, JNK and p38 were however similarly induced 
between TLR4-stimulated wildtype and Dok3-deficient macrophages. We next 
assayed for NFB activation by looking at IB degradation via western blot (Figure 
IV-5). However, IB degradation rate was comparable between TLR4-stimulated 
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wildtype and Dok3-deficient macrophages. These results suggest that there appears to 
be no requirement for Dok3 in the major signaling pathways downstream of TLR4 
(including MAPKs and NFB) with the dosage of LPS (100 ng/ml) that was utilized 
in the assays. A previous study identified that sublevels of LPS can be associated with 
the severity of pathogenesis in various human inflammatory diseases. Thus the LPS 
dosage utilized in experiments can be categorized into high and low dose and may 
yield different experimental outcomes. So far, we have been using 100 ng/ml LPS in 
our experiments. This is considered a high dosage of LPS stimulation in various 
literatures (Maitra et al., 2011; Stelter et al., 1998; Xu et al., 2007). As such, it may 
be possible that there could be some dosage-dependent effects for TLR4 signaling by 
Dok3.  
 





 macrophages were stimulated with 100 ng/ml LPS for the indicated timepoints. 
Cells were lysed and analyzed by immunoblotting with phospho-antibodies to (A) ERK, (B) JNK and 
(C) p38. Loading of equal amount of lysates were verified by immunoblotting with antibodies to total 
ERK, JNK and p38. Data shown are representative of three independent experiments. 





Figure IV-5 Normal NFB activation in LPS-stimulated Dok3-/- macrophages.  
Wildtype and Dok3
-/-
 macrophages were simulated for various times with 100 ng/ml LPS and examined 
by Western blot analysis for the degradation of IB. Anti-p38 blot was included as control for equal 
loading of cell lysates.  
4.6 Low Dose of LPS stimulated Dok3-deficient macrophages exhibit 
defective ERK activation 
To test out this hypothesis, we stimulated wildtype and Dok3-deficient macrophages 
with a low dose of LPS (10 ng/ml) in a time-dependent manner and assayed for 
phosphorylation of ERK by western blotting. We show here in Figure IV-6 that the 
activation of ERK was defective in Dok3-deficient macrophages as compared to 
wildtype by this low LPS dose stimulation. The data indicated that there is LPS 













 macrophages were stimulated with 10 ng/ml LPS for the indicated timepoints. 
Cells were lysed and analysed by immunoblotting with phospho-antibodies to ERK. Loading of equal 
amount of lysates were verified by immunoblotting with antibodies to total ERK. Data shown are 
representative of two independent experiments. 
4.7 Dok3 -/- Mice are Resistant to Septic Shock upon Immunization with low 
dose LPS 
The septic shock model is established laboratory protocols that assess the ability of D-
GalN-sensitized mice to mortality. Other factors that contribute to septic shock 
include prostaglandins, COX2 and proinflammatory mediators such as iNOS as well 
as excessive production of type I IFN (Ketteler et al., 1998; Rabuel et al., 2004). As a 
lower threshold of TLR4 signaling appears to require Dok3, we investigated if these 
mutant mice were viable with a low dose of LPS challenge in a septic shock model. 
We show here in Figure IV-7 that Dok3-deficient mice are resistant to LPS-induced 
septic shock whereas all the wildtype mice succumbed after 40 hours from 
immunization. The data suggest that Dok3 is required as a positive regulator in a 
suboptimal dose of TLR4 signaling. 




Figure IV-7 Dok3-deficient mice are more resistant to low dose LPS-induced septic shock.  
Wildtype (black line) and Dok3
-/-
 mice (red line) were injected with 10 ng LPS and 20 mg of D-GalN. 
The dose of LPS was calculated per 20 g of body mass. Survival of mice was monitored for over 24 hr. 
Statistical significance was established by paired student‟s t test, *p<0.05.  
4.8 Impaired Production of TNF by Dok3 Deficiency in low dose TLR4 
Signalling 
The TNF-mediated liver damage is one of the key contributing factors to the 
mortality of mice in D-GalN-dependent LPS septic shock (Dejager and Libert, 2008). 
As the above results indicate that Dok3 deficiency confers resistance to death in a 
suboptimal dose of LPS-induced sepsis, it is possible that the TNF proinflammatory 
cytokine production may be disregulated. To investigate this possibility, we 
stimulated in vitro wildtype and Dok3-deficient macrophages with varying dose of 
LPS including 10 ng/ml and 100 ng/ml and assayed for TNF production by its 
protein secretion and protein expression. As shown in Figure IV-8 whereas we were 
able to detect by ELISA TNF production in the suboptimal dose LPS-stimulated 
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wildtype macrophages, this was defective in Dok3-deficient macrophages treated in a 
similar fashion. To confirm these findings, we also stimulated wildtype and Dok3-
deficient macrophages with low and high doses of LPS and assayed for TNF protein 
expression by western blotting. As shown in Figure IV-9, TNF protein expression 
was not detectable in untreated wildtype macrophages; however this TNF protein 
expression can be detected when treated with both low and high dose of LPS. In 
contrast, TNF protein expression was only defective in Dok3-deficient macrophages 
when treated with a low dose of LPS but not with a high dose of LPS. 
 
Figure IV-8 Dok3 regulates TNF gene induction in low dose LPS-stimulated macrophages.  
Real-time qPCR analysis of TNF mRNA expression in wildtype (black columns) and Dok3-/- (white 
columns) macrophages stimulated with 10 ng/ml LPS for 2 hr. The amount of TNF mRNA 
expression was normalized to that of actin mRNA. Figures shown are representative of at least two 
independent experiments.  




Figure IV-9 Defective TNF production in low dose LPS-stimulated Dok3-/- macrophages.  
Wildtype and Dok3
-/-
 macrophages were stimulated with 10 ng/ml (low dose) and 100 ng/ml (high 
dose) LPS for 2 hr. Cells were lysed and analyzed by immunoblotting with TNF antibodies. Loading 
of equal amount of lysates were verified by immunoblotting with antibodies to total ERK. Data shown 
are representative of two independent experiments. 
 
4.9 Impaired Production of COX2 and induction of iNOS mRNA Expression 
by Dok3 Deficiency in TLR4 Signalling 
In addition to an excessive production of TNF that can contribute to sepsis in mice, 
other known components of proinflammatory mediators of LPS-induced sepsis 
include prostaglandins such as COX2 and the reactive oxygen species such as iNOS. 
We have shown in in vitro experiments that TNF production in a suboptimal dose of 
LPS stimulation requires Dok3 and in vivo, this defect in TNF production by Dok3 
deficiency confers resistance in the mice upon being challenged with low dose LPS. 
We investigated further if COX2 and iNOS induction may be perturbed by Dok3 
deficiency. As shown in Figure IV-10, when wildtype macrophages are stimulated for 
6 hours with LPS, COX2 protein expression was readily detected by western blotting. 
The COX2 protein expression however was defective by Dok3-deficiency when 
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stimulated in the same manner. We also stimulated wildtype and Dok3-deficient 
macrophages with LPS and measured iNOS gene expression via real-time qPCR and 
show here in Figure IV-11 that the gene expression of iNOS was defective in TLR4-
stimulated Dok3-deficient macrophages but not in TLR4-stimulated wildtype 
macrophages. Taken together, these data indicated that Dok3 is required to induce 
TNF, COX2 and iNOS production in a suboptimal threshold of TLR4 signaling. 
 





 macrophages were stimulated with 10 ng/ml (low dose) LPS for 6 hours. Cells 
were lysed and analyzed by immunoblotting with COX2 antibodies. Loading of equal amount of 
lysates were verified by immunoblotting with antibodies to total ERK. Data shown are representative 
of three independent experiments. 
 
Figure IV-11 Dok3 regulates iNOS gene induction in low dose LPS-stimulated macrophages.  
Real-time qPCR analysis of iNOS mRNA expression in wildtype (black columns) and Dok3
-/-
 (white 
columns) macrophages stimulated with 10 ng/ml LPS for 2 hr. The amount of iNOS mRNA expression 
was normalized to that of actin mRNA. Figures shown are representative of at least 2 independent 
experiments.  
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4.10 Proteomic Analysis of Novel Dok3 Interacting Partner upon BMDM 
Stimulation with TLR4 Agonist 
The results obtained so far with examining the role of Dok3  in TLR4 signaling reveal 
that the Dok3 regulatory role in TLR4 signaling is dependent on TLR4 signaling 
strength and dosage. In addition, we note that there appears to be no requirement of 
Dok3 in the MyD88 signaling axis in TLR4 activation in terms of inflammatory 
cytokine production but Dok3
-/-
 mice are yet susceptible to low dose LPS septic 
shock. This makes Dok3 an interesting but complex target in TLR4 signaling and 
prompted us to ask if there could be other, novel interacting partners of Dok3 in TLR4 
signaling. Thus we undertook a proteomic approach to examine possible Dok3 
interacting partners in TLR signaling via mass spectrometry (MS). We show here in 
Figure IV-12, a list of different protein targets interacting with Dok3. One of these 
candidate targets that was pulled down by MS and is of interest is ABIN1. 
 
Figure IV-12 Mass spectrometry analysis of RAW264.7 stimulated with LPS.  
(A) Protocol for mass spectrometry analysis and Coomassie Blue gel staining of immunoprecipitated 
RAW264.7 cell lysates stimulated with LPS and poly(I:C). (B) Pie chart demonstrating the novel 
proteins identified via mass spectrometric analysis of interacting partners of Dok3. 
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4.11 Dok3 interacts with ABIN1 in vitro 
The A20-binding inhibitor of NFκB activation (ABIN1), also named as Naf1 (Nef-
associated factor-1) or TNIP1 (TNFAIP3-interacting protein 1) was identified by 
yeast-two hybrid screening as an interacting partner to A20 (Heyninck et al., 1999). 
A20 was a known negative regulator of NFB signaling and ABIN1 was found to 
modulate its inhibitory effect (Vereecke et al., 2009). NFB played diverse roles in 
cellular gene expressions and processes (Gilmore, 2006). ABIN1 was demonstrated in 
one study where it can bind the MAP kinase ERK2 and down-regulate ERK2 
signaling (Fang et al., 2011). ERK2 activation was known to be critical for cell 
growth and differentiation as well as apoptosis (Wada and Penninger, 2004). ABIN1-
deficient mice were generated in 2009 but it was embryonically lethal with death 
resulting from fetal liver apoptosis, anemia and hypoplasia (Oshima et al., 2009). 
 
To examine and validate our MS results on whether the candidate protein ABIN1 
does indeed interact with Dok3 in TLR signaling, we stimulated wildtype 
macrophages in a time dependent manner with LPS and immunoprecipitated Dok3 
and examined for ABIN1 interaction by western blotting. As shown in Figure IV-13, 
we could detect ABIN1 binding to Dok3 upon stimulation with LPS. This data 
confirms the results obtained with MS analysis and suggested that ABIN1 is a novel 
binding partner of Dok3 in TLR4 signaling in a physiological setting. 




Figure IV-13 Dok3 interacts with ABIN1 upon LPS stimulation.  
BMM were stimulated for various times as indicated with 1 g/ml LPS and subsequently lysed. Dok3 
was immunoprecipitated and probed with antibodies to ABIN1. Figure shown is representative of two 
independent experiments.  
4.12 A20 expression is impaired by Dok3 Deficiency in TLR4 signalling 
ABIN1 was originally identified as an A20 interacting partner. A20 was demonstrated 
in a study to form a signaling complex with TPL-2 and p105 (Lang et al., 2004) and 
TPL-2 was known to be degraded upon LPS signaling (Beinke et al., 2004). Next we 
investigated if TPL-2, A20 and p105 protein expression could be perturbed in the 
absence of Dok3. To this end, we stimulated wildtype and Dok3-deficient 
macrophages with LPS and examined the protein expression of TPL-2, A20 and p105. 
We show here in Figure IV-14 that whereas TPL-2 degradation and p105 protein 
levels by LPS stimulation were comparable between TLR4-stimulated wildtype and 
Dok3
-/-
 macrophages, A20 protein expression was defective from Dok3 deficiency in 
TLR4 signaling. This data suggest that Dok3 protein may be required for some 
regulatory role in A20/ABIN1 dependency in TLR4 signaling. 
 
 









 macrophages were stimulated with 100 ng/ml LPS for the indicated timepoints. 
Cells were lysed and analyzed by immunoblotting with antibodies to (A) TPL-2, (B) A20 and (C) p105. 
Loading of equal amount of lysates were verified by immunoblotting with antibodies to total HDAC1. 
Data shown are representative of two independent experiments. 
4.13 Discussion 
Dok1 and Dok2 have been demonstrated to be negative regulators of TLR4 signalling 
(Shinohara et al., 2005). Negative regulators of signal transduction pathways may 
function in three different modes of actions. First, they can function to keep effector 
proteins from being activated in the quiescent state in the cells. Second, they can 
function to control the strength and threshold of activated signalling proteins at an 
appropriate level. Third, they can function to dampen or downregulate an on-going 
activated response (Sanada et al., 2008).  
 
Dok3 differs from Dok1 and Dok2 in that it does not bind rasGAP (Mashima et al., 
2009). It is unknown if this unique differential property of Dok3 from its other protein 
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family members will confer it a different identity in TLR signal transduction. The role 
of Dok3 in TLR4 signalling has not been demonstrated to date. Therefore, we utilised 
Dok3-deficient mice generated in our laboratory to examine the role of Dok3 in TLR4 
signalling as part of this study. TLR4 signalling is unique as it utilises four adaptor 
proteins in its signal transduction pathways (Sandor and Buc, 2005). Unexpectedly 
and interestingly, we found that Dok3 positively regulates TLR4 signalling in a dose-
specific manner, in contrast to its other family members Dok1 and Dok2. We 
demonstrated that although Dok3 is dispensable for high dose TLR4 stimulation in 
signalling to major signal transduction pathways including NFB and MAPKs, Dok3 
is however required for low dose TLR4 stimulation in signalling to activate ERK. 
Moreover, the requirement of Dok3 effect in low dose TLR4 signalling was 
exemplified in low-dose LPS sepsis model and this was attributable to the combined 
defects observed in proinflammatory TNF secretion, activation of prostaglandins 
including COX2 and iNOS as well as in IFNβ production that resulted in the Dok3-
deficient mice being more resistant to mortality as compared to wildtype mice. 
 
The MyD88 signalling axis downstream of TLR4 is known to mediate 
proinflammatory cytokine production whereas the signalling mediate by TRIF 
downstream of TLR4 signals to produce IFNβ (Yamamoto et al., 2003). In this 
context, IL-6, TNF (MyD88-dependent) and IFNβ (TRIF-dependent) production in 
TLR4 signalling requires Dok3 and suggest that Dok3 is required in both MyD88-
dependent as well as TRIF-dependent pathway downstream of TLR4 for signalling to 
IFNβ. However, the signalling defect with Dok3-deficient cells was not easily 
observable when TLR4 signalling strength was increased. This perhaps suggests that 
Dok3 activation in TLR4 signalling is delicate and functions more as a modulator in 
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fine-tuning TLR4 activation. This may also explain why Dok3 loss-of-function 
phenotype could only be detectable when TLR4 signalling strength (i.e. LPS dose) is 
reduced in our studies. 
 
Our hypothesis is that Dok3 may not only participate in TLR4 signalling via the 
current known signalling proteins such as MyD88 and TRIF, but that more proteins 
could be involved. To address this hypothesis, a MS analysis was performed to 
uncover novel proteins interacting with Dok3 in TLR signalling. A most interesting 
target that was immunoprecipitated in our TLR4 Dok3-interactome studies was 
ABIN1. ABIN1 is known as a negative regulator for TNF production. ABIN1-
deficient mice were generated previously and reported to exhibit embryonic lethality. 
However this developmental defect can be reversed by crossing the mice with TNF-
deficient homozygous background mice (Oshima et al., 2009). There are a number of 
studies on ABIN1 and its role in TLR signalling. For example, ABIN1 functions as a 
negative regulator of antiviral signalling by cooperating with TAXBP1 and A20 (Gao 
et al., 2011). In a separate study, ABIN1 was found to negatively regulate TLR-
induced C/EBPβ activation and help protect the host from inflammatory disease 
(Zhou et al., 2011). It is intriguing as to why Dok3 and ABIN1 interact. There are 
several biological questions surrounding this interesting phenomena that warrant 
further investigation. First, what is the relationship between Dok3 and ABIN1? Dok3 
appears to be a positive regulator in TLR signalling in our study whereas ABIN1 was 
documented as a negative regulator in other related studies (Fang et al., 2011; Oshima 
et al., 2009; Zhou et al., 2011). We speculate that ABIN1 may function to switch off 
TNF production by Dok3 in TLR signalling upon activation to limit the excessive 
effects of inflammation that may be deleterious to the host cell. This observation is 
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consistent by our studies where we observed that the ABIN1 protein increasingly 
interacts with Dok3 in TLR4 stimulation in our immunoprecipitation experiments in 
macrophages when we pulled down Dok3. Second, how does Dok3 and ABIN1 
effector functions affect each other in TLR-mediated signal transduction pathways? 
Dok3 contains a PH domain, a PTB domain and a SH2-target motif domain 
containing tyrosine residues whereas ABIN1 contains the ABIN homology domain 
(AHD), Ubiquitin Binding domain in ABIN proteins and NEMO (UBAN) and the 
Nucleotide binding domain (NBD). There appears to be no homologous or specific 
known domains of these two proteins that may mediate interaction. However, it is 
noteworthy that one particular post-translational modification (PTM), ubiquitination, 
is gaining increasing importance in signal transduction pathways as it is one critical 
way whereby immune homeostasis and balance is achieved. It may be possible that 
Dok3 may be ubiquitinated for either K48-mediated degradation or ubiquitin K63-
linked activation and ABIN1 may act or inhibit PTM for subsequent biological 
activity. Last but not least, it is useful to understand if the phenotype of ABIN1 in 
TLR signalling is similar to Dok3 deficiency and if a combinatorial deletion in both 
molecules could yield a more striking phenotype as compared to the single knockout 
mice. However, ABIN1 is known to have a broad and indispensible role in organism 
development and its deletion in mice leads to embryonic lethality. Given all the 
implications, it is possibly necessary to investigate the defect of ABIN1 loss of 
function in TLR signalling in mice via a conditional knockout model. Another way to 
study the combined loss of function effect of Dok3 and ABIN1 would be to introduce 
siRNA to ABIN1 in Dok3
-/-
 cells to remove ABIN1 expression and subject the 
double-deficient cells to in vitro immunological assays in TLR signalling to study 
combined loss-of-function biological effects. 




Another family member of ABIN, ABIN2 has been demonstrated to form a protein 
complex with TPL-2 and p105, keeping them in their inhibitory state in TLR4 
signalling. Upon TLR4 crosslinking, ABIN2 gets sequestered, leading to the 
degradation of p105 in the proteasome and the release of p50 homodimer to mediate 
NFB activation. On the other hand, TPL-2 can activate the MAPK signal 
transduction pathway for TNF and COX2 production via ERK signalling (Gantke et 
al., 2011). We postulate here that ABIN1 may function in the same manner as ABIN2 
in TLR4 signalling and the sequestration of ABIN1 from the signalosome complex 












Figure IV-15 A model for ABIN2 role in TLR4 signalling.  
Regulation of TPL-2 through IKK-induced p105 proteolysis. TPL-2 is confined to a cytoplasmic 
complex with the NFκB1 precursor protein p105, and the ubiquitin-binding protein ABIN2. NFκB1 
p105 has multiple functions. First, it serves as a precursor molecule for the NFκB1 p50 subunit, which 
is generated by limited proteolysis (processing) of p105 by the proteasome, and removes p105's C-
terminal. Second, p105 functions as a classical IκB, retaining associated NFκB subunits in the 
cytoplasm. Cellular stimulation with TLR ligands, for example LPS, induces the formation of receptor 
proximal complexes that trigger activation of the MAP3K, TAK1. Activation loop phosphorylation of 
IKK2 by TAK1, in turn, activates IKK2 to phosphorylate the target residues S927 and S932 in p105, 
creating a binding site for the SCFβTrCP ubiquitin E3 ligase complex. K48-linked ubiquitination of 
p105 by SCFβTrCP triggers its complete degradation by the 26S proteasome. IKK-induced proteolysis 
of p105 releases associated NFκB dimers, which then translocate to the nucleus and modulate 
expression of target genes, similar to the activation of NFκB dimers in the classical pathway. Stimulus-
induced p105 proteolysis also couples activation of NFκB pathways to MAP kinase signalling by 
releasing TPL-2 from p105 inhibition. After liberation from p105, TPL-2 directly phosphorylates MEK 
and thereby activates downstream ERK MAP kinase signalling. Proteasomal degradation of p105 also 
releases ABIN2 from association with p105 and TPL-2. The function and downstream targets of 
ABIN2 are not known (Gantke et al., 2011). 
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5.1 General Discussion 
To gain more insight into the physiological role of adaptor protein Dok3 in the innate 
signalling pathway, we analysed the effects of Dok3 deficiency in various PRRs 
including membrane TLR4, endosomal TLR3 and cytosolic sensor RIG-I. We show 
in this study that Dok3 plays a critical role in antiviral PRRs signalling including 
TLR3 and RLR signalling. Dok3 is phosphorylated upon TLR3 and RLR engagement 
and its deficiency impaired the secretion of proinflammatory cytokines and IFNβ in 
naked poly(I:C)-treated macrophages as well as IFNβ induction in transfected 
poly(I:C)-treated macrophages. As a result of reduced cytokine production, Dok3
-/-
 
mice were more resistant to D-GalN-sensitized poly(I:C)-induced septic shock. In 
these aspects, the responses of Dok3
-/-
 macrophages and mice to poly(I:C) stimulation 




 cells and mice. Both TLR3 and BTK-deficient 





 mice were also resistant to D-GalN/poly(I:C)-induced septic 
shock (Alexopoulou et al., 2001; Lee et al., 2012). These observations suggest that 
Dok3 could be part of the TLR3 signalling pathway. 
 
Engagement of TLR3 triggers the induction of multiple signalling pathways that 
culminate in the activation of NFB, AP-1 and IRF3 that are critical for the 
production of cytokines and interferons (Vercammen et al., 2008). At the biochemical 
level, our data indicated that Dok3-deficiency specifically affects TLR3-induced IRF3 
activation and this led us to hypothesize that Dok3 could act somewhere along the 
TRIF/TBK1/TRAF3 signalling axis to IRF3 for IFNβ production. The de novo 
identity of Dok3 as an adaptor protein prompted us to examine if Dok3 is required to 
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function as a scaffold protein in TLR3 signalling to mediate the production of IFNβ. 
We ectopically expressed HA and/or FLAG-tagged plasmids of Dok3 independently 
with the various known signalling proteins involved in TLR3 pathway including 
TRIF, TBK1, TRAF3 and BTK and found that Dok3 interacts directly with BTK, 
TBK1 and TRAF3 but not with TRIF. As such, Dok3 may function as an adaptor 
protein at the level of TBK1 and TRAF3 to enable TBK1 and TRAF3 to form a 
complex that is known to be necessary for IRF3 activation. We further identified the 
SH2-target motif of Dok3 as important for its interaction with TBK1 and the PTB 
plus SH2-target motif for TRAF3. Consistent with this finding, the co-expression of 
Dok3 with TBK1 plasmid synergistically promoted IFNβ production in an IFNβ 
luciferase assay and a mutant Dok3 plasmid lacking the SH2-target motif but not the 
PH domain could ablate this enhanced IFNβ promoter effect. The net effect of a 
resultant loss of the Dok3 effect of interacting with TBK1 downstream of TLR3 is a 
compromised TBK1 activity, and the subsequent IRF3 phosphorylation and its 
nuclear translocation to bind the ISRE consensus region of the IFNβ enhanceosome 
and optimally induce IFNβ. It was recently demonstrated that BTK is the tyrosine 
kinase that phosphorylate critical tyrosine residues on TLR3 in order to initiate 
antiviral responses (Lee et al., 2012). We also showed in our studies that Dok3 
undergoes tyrosine phosphorylation in its carboxyl tail. Our work also examined if 
BTK could be the tyrosine kinase that phosphorylate Dok3 and this was indeed the 
case. In addition, BTK and Dok3 could interact directly as demonstrated from our 
overexpression studies using HEK293T cells.  
 
One of the most intriguing questions in this project lies in where Dok3 localizes upon 




and Dok3 is known to be translocated to the plasma membrane via its PH domain in 
BCR signalling (Stork et al., 2007). However, the TRIF multimer complex that forms 
upon TLR3 signalling was shown to translocate from the receptor to form speckles in 
the cytosol (Funami et al., 2007). If Dok3 was part of this complex, it may suggest 
that Dok3 activity following TLR3 stimulation is independent of its PH domain. This 
would contrast with the current knowledge indicating the importance of Dok3 PH 
domain for BCR signalling (Stork et al., 2007) adding further complexity into the 
biology of Dok3‟s regulation. Further experiments such as confocal analysis of Dok3 
localization in TLR3 stimulation will distinguish these possibilities. 
 
In addition to the above findings, our studies indicated that Dok3 may participate in 
signalling pathways leading to IFNβ production in multiple receptors systems 
including TLR and RLR. This view comes from the fact that Dok3 absence leads to 
defective IFNβ signalling not only upon TLR3 and TLR4 activation (which signals 
through TRIF) but also via stimulation with transfected poly(I:C) and upon influenza 
virus infection where these stimulants were known to engage RLRs and signals 
through IPS-1 for IFNβ production. The commonality between signalling via the 
TLRs including TLR3 and TLR4 and the RLRs pathways is that despite the 
differential usage of adaptor proteins, they converge on TBK1 and TRAF3 to activate 
IRF3 transcription factor for IFNβ production. We have shown that in Dok3, it does 
not bind to TRIF, but instead bind to TBK1 via its SH2-target motif for signalling to 
IFNβ. We hypothesize that Dok3 might not interact with IPS-1 in this situation. 
Future experiments will be aimed at investigating this possibility. However, based on 
our current understanding of the Dok3 role in TLR3 signalling, Dok3 may not be 
required to bind IPS-1 (analogous to the fact that it does not bind TRIF) to signal 
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downstream of RLRs engagement for IFNβ production and the binding to TBK1 in 
RLR-mediated signalling may already be sufficient for Dok3 to exert its effect and 
induce IFNβ in RLR signalling. 
 
The other question is whether BTK is required to phosphorylate Dok3 in RLR-
dependent signalling instead. This is because although BTK is required to 
phosphorylate Dok3 in TLR3 signalling, it is dispensable for the RLR-mediated 
induction of IFNβ however (Lee et al., 2012). Dok3 may have a much broader and 
more significant role than BTK in the signal transduction pathway leading to an 
antiviral response since we showed that Dok3 is required for both TLR3 and RLR 
signalling pathway whereas BTK‟s role is only restricted to TLR3 only. It is also 
important to note that the multifaceted role of Dok3 as a modulator of antiviral 
interferon makes it a much more attractive therapeutic target or approach than those 
drugs that simply inhibit or activate kinases or phosphatases as shutting down or 
turning on a whole signal transduction pathway may yield a more detrimental 
outcomes in disease control as compared to fine tuning the effects to produce a better 
option. 
 
We demonstrated that Dok3 is also involved also in TLR4-mediated TRIF dependent 
pathway of signalling to IFNβ. However, TLR4 is known to be the receptor for 
endotoxin responses that is usually activated by microbial infections. Thus, the role of 
Dok3 in TLR4 may be much broader than thought of currently as being required for 
the activation of IFNβ downstream of TLR4. We examined the effects of Dok3 in 
TLR4 signalling by LPS stimulation and showed that there is a dose-dependent 




investigated the requirement of Dok3 in the TLR4-induced MAPK using a higher 
dose of stimulant, there was no observable differences between wildtype controls and 
Dok3-deficient macrophages. More strikingly however, there was a defect in 
activating ERK MAPK by Dok3-deficiency when the cells were stimulated with a 10-
fold dosage decrease of the LPS stimulant. The resultant effects of a lower signalling 
strength of LPS yielded more accompanying phenotypes in Dok3-deficient mice and 
cells including the mutant mice being resistant to LPS-induced sepsis and an impaired 
TNF proinflammatory cytokine production. From such observations and findings, 
we speculate that Dok3 may be involved in endotoxin tolerance and future studies 
will investigate this possibility. Endotoxin tolerance is characterised by refractive 
responses in immune cells subsequent to LPS challenge prior to its initial stimulation 
in terms of inflammatory reaction (Chae, 2002). Our understanding of Dok3‟s 
requirement in only suboptimal TLR4 signalling may drive us to further investigate if 
the phenotype of Dok3-deficiency may perhaps only be unveiled in a subsequent LPS 
challenge after prior low dose LPS exposure in an endotoxin tolerance model.  
 
The lack of effects of Dok3 on TLR4 signalling in impacting some of the major signal 
transduction pathways that were examined including NFB and MAPKs have also 
prompted us to ask if there could be other novel molecules involved in TLR4 
signalling that are associated with Dok3. In answer, we undertook a MS proteomics 
approach to identify novel proteins that could interact with Dok3 in this pathway. We 
immunoprecipitated Dok3 from TLR3- and TLR4- stimulated RAW cell (or BM 
derived macrophages), lysates and subjected it to MS to identify the possible 
candidates. Some of the candidates that were identified were of significant interest. 
One of these interesting candidates that are related to our research focus is ABIN1. 
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We decided to focus our understanding on the role of Dok3 interaction with ABIN1 as 
this interaction may be involved in the regulation of the TNF contributing role in 
sepsis. The pro-inflammatory response in LPS signalling needs to be a tightly 
regulated process and this positive regulation was balanced by the up-regulation of 
several negative regulators. The NFB inhibitor, IB was up-regulated along with 
TNFAIP3, also known as A20, and its interacting partner TNIP1 (ABIN1). A20 and 
ABIN1 inhibit the activation of NFB through the de-ubiquitination of IKK 
(NEMO) (Song et al., 1996). We found that Dok3-deficiency results in defective 
TNF production and this translates to better protection against sepsis in the LPS 
challenge in vivo. This suggests that Dok3 functions as a positive regulator in LPS-
induced TNF production and in its absence, the defective production of this 
deleterious cytokine helped protect the mice from the lethal effects of sepsis. In 
contrast, ABIN1 was demonstrated to be a negative regulator of NFB and TNF 
production and conditional ABIN1 KO mice showed that they were more susceptible 
to mortality by LPS-induced sepsis compared to wildtype mice (Zhou et al., 2011). It 
is therefore intriguing that we found these two proteins in our MS studies and 
immunoprecipitation studies from LPS-stimulated macrophages. We hypothesized the 
following scenarios.  
 
First, Dok3 acts as a positive regulator and at the same time binds to a negative 
regulatory protein to control the duration and magnitude of the inflammation process 
to avoid overt inflammation. This is a scenario whereby cross-talk between signalling 
pathways happen and the cell evolve a delicate balance by having both positive and 





Second, it was found in BCR signalling that Dok3 sequesters Grb2 away from the 
GTP exchange factor (GEF) son-of-sevenless (SOS), thereby preventing efficient 
activation of the Ras/ERK cascade (Stork et al., 2007). A similar scenario may 
happen whereby in a physiological setting upon LPS signalling, ABIN1 has to be 
turned on to downregulate the positive signalling to TNF, and over time Dok3 
functions then begin to sequester away ABIN1. This may explain why in Dok3
-/-
 
macrophages, where there is a lack of Dok3 protein expression to sequester the 
activating function of ABIN1, ABIN1 functions as a constitutive negative regulator 
with A20 and prevents TNF production by inhibiting NFB activation (Figure V-1).  
 
 
Figure V-1 Hypothetical model of Dok3 and ABIN1 roles in TLR4 regulation of TNF.  
Upon activation of TLR4 by LPS, ABIN1 has to be turned on to downregulate the positive signalling to 
TNF, and Dok3 functions to sequester ABIN1 over a regulated timeframe to allow TNF production 
to occur in order to maintain immune homeostasis. However in the absence of Dok3 there is no 
sequestration of ABIN1 from A20 and therefore these two proteins are constitutive active and 
continually inhibit the NFB pathway from activating TNF production.  
 
GENERAL DISCUSSION  
V-136 
 
This would explain the lack of TNF being detected by Dok3-/- macrophages upon 
LPS signalling. However, the kinetics of Dok3 and ABIN1 regulation and activation 
has to be carefully considered as critical parameters in this TLR-induced setting to 
definitively place the hierarchy of these proteins in the signalling pathways evoked by 
LPS. 
 
Third, ABIN1 was demonstrated to be able to bind the MAP kinase ERK2 and down-
regulate ERK2 signaling. We have also observed that with a suboptimal dose of LPS 
signaling, Dok3-deficient macrophages exhibited defective activation of ERK. To 
take these two observations together, it appears that Dok3 and ABIN1 may have some 
opposing effects in regulating ERK activation. This would also be consistent with 
their regulatory functions in that Dok3 is a positive while ABIN1 is a negative 
regulator from ours and other studies (Oshima et al., 2009; Zhou et al., 2011). It is 
interesting to check if Dok3 may perhaps regulate the protein expression of ABIN1. 
One likely scenario is that if this is the case, it may explain that in the absence of 
Dok3 in macrophages, ABIN1 mRNA and protein expression may be abrogated as a 
result or even be increased, if Dok3 negatively regulate ABIN1. In this postulation, 
there will be more ABIN1 protein which in turn binds to ERK2 and inhibit its 
activation. This possibility may also be extended to explain how Dok3 deficiency 
leads to an increase in ABIN1 expression which in turn leads to a constitutive 
inhibition of TNF production. More experiments would have to be performed to 
confirm these hypotheses. 
 
In summary, we demonstrated that Dok3 is involved in TLR signalling, namely with 




interferon, IFNβ. Here, we showed that in contrast to other Dok family members that 
were demonstrated to be negative regulators of TLR signalling (Shinohara et al., 2005; 
Zhou et al., 2011), Dok3, to our surprise exists as a positive regulator in inducing 
IFNβ. We defined in detail the mechanism of the Dok3 positive regulatory role in 
TLR3 and TLR4 signalling to IFNβ and found BTK to be the kinase involved in 
phosphorylating Dok3 for its regulatory function. Dok3
-/-
 mice are more resistant to 
poly(I:C)-induced endotoxin shock, owing to a defective IFN signalling.  
 
We see a scenario for the role of Dok3 in TLR3 signalling with our current data. Upon 
activation by dsRNA, it leads to the dimerisation and activation of TLR3. This 
possibly results in the recruitment of TRIF and BTK of which BTK is required to 
fully phosphorylate TLR3 at tyrosine 759 residue (Lee et al., 2012). Previously, c-
SRC was shown to be induced by dsRNA and leads to IRF-3 activation.  However 
Lyn, a SRC family member could not directly phosphorylate TLR3 (Johnsen et al., 
2006).  Indeed, c-SRC was shown to associate with TRAF3 and this occurred further 
downstream in TLR3 signalling.  PI3K is then recruited to phosphorylate TLR3 on 
tyrosine 759 residue to mediate IRF3 activation via the AKT pathway. On the other 
hand, BTK activates the TRIF-dependent major signalling pathways downstream of 
TLR3 including MAPKs, NFB and TBK1-mediated IRF3 activation. All of these 
cumulate in an effective assembly of a functional -interferon enhanceosome to 
secrete IFN, a critical type I IFN for an anti-viral immune response. Additionally we 
found that Dok3 played a critical adaptor function to mediate the TBK1 signalling 
pathway to induce IFNβ. Furthermore upon TLR3 stimulation, BTK is activated and 
interacts with TRIF. Dok3 may also shuttle or bridge various signalling components 
to signalosome by interacting with BTK. Dok3 then binds to TBK1 via its SH2-target 
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motif and TRAF3 via its PTB and SH2-target motif. This adaptor function of Dok3 
further allows TBK1 and TRAF3 to tether to TRIF for TBK1‟s activation. An 
activated TBK1 on serine 172 residue is now able to function as a serine threonine 
kinase and phosphorylate its substrate IRF3 on serine 396 which allows its 
dimerisation and nuclear translocation and binding to the ISRE region of the DNA to 
induce optimal IFNβ production. The AKT pathway activated by PI3K binding to the 
tyrosine phosphorylated residues of an activated TLR3 was also found to be defective 
by Dok3 deficiency. More recently, this pathway of AKT activation was found to 
converge downstream in the TLR3 pathway to activate TBK1 leading to an optimal 
activation of IRF3. Since lack of Dok3 affects AKT activation, it may be possible that 
Dok3 perhaps interact with AKT or interferes with TLR3 signalling by AKT in some 
way. 
 
Finally, since dsRNA is a key replication intermediate of several viruses and is 
recognized by TLR3, our work suggests that drugs that activate Dok3 could be 
relevant for the treatment of various viral infections including dengue and influenza. 
However, there is to date no known chemical compound that could activate Dok3. 
Any chemical activator of Dok3 would have to activate the enzyme at an appropriate 
level and only transiently in order to prevent excessive inflammation in the host.  
 
We found BTK to be the kinase that activates Dok3 in our studies. There are known 
chemical inhibitors of BTK undergoing clinical trials for the treatment of B-cell 
driven autoimmune diseases and B-cell malignancies such as non-Hodgkin 
lymphoma, mantle cell leukemia and chronic lymphocytic leukemia. BTK-inhibitors 




limit excessive inflammatory responses that could have a deleterious effect on 
patients. Some examples include the pandemic flu and SARS coronavirus infections 
where excessive host response results in a “cytokine storm” that ultimately kills the 
host. BTK-inhibitors could theorectically be used to dampen the “cytokine storm” and 
therefore appears to be a potential attractive target.  
 
Although the current trend in therapeutic design appears to be directed towards 
kinases or phosphatases that either switch “on” or “off” signalling pathways, it may 
not be ideal as shutting down or activating bulk pathways may lead to detrimental or 
undesirable outcomes or side effects. We propose that new screening methodologies 
for drug targets be aimed at activating or deactivating proteins involved in moderation 
or “fine-tuning” specific responses, for example Dok3 in this case for antiviral 
studies. This is so as our research findings show, Dok3 is specific in activating the 
TBK1-IRF3 signalling axis to IFNβ and therapeutics based on targeting specificity in 
particular pathways may be a much more desirable prophylactic measure in clinical 
requirements for viral disease control. 
 
In addition to Dok3‟s role in TLR3 signalling, we have also examined its role in 
TLR4 signalling. TLR4 signalling is also required to signal IFNβ production via the 
TRIM-TRAM pathway. Our postulation is that Dok3 also plays a role in TLR4 
signalling to IFNβ. Indeed we found that Dok3 impacts TBK1 and IRF3 activation 
and subsequently IFNβ production. TLR4 activation also evokes major signalling 
events including NFB and MAPKs for the production of inflammatory cytokines 
required in an anti-microbial immune response. This explicit inflammation process 
has to be tightly regulated otherwise it will lead to sepsis (Raetz and Whitfield, 2002). 
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We found that Dok3 is required for TNF production in a suboptimal dose of TLR4 
activation and its absence confers resistance to mice in an LPS-induced sepsis model. 
In addition, many other key mediators of sepsis in mice including COX2 and iNOS 
activation were found to be defective with Dok3 deficiency. In contrast, there appears 
to be no major requirement for Dok3 when TLR4 signalling strength was increased. 
This phenomenon suggested that Dok3 may probably be required for a condition 
known as endotoxin tolerance where prior exposure of cells to suboptimal dose of 
endotoxin will confer a refractory response upon re-stimulation with a lethal dose 
later on. Further investigations in this area will be performed to prove the hypothesis. 
While this report writing was in progress, a paper was published describing Dok3 as a 
negative regulator of TLR4 signalling in the same manner as Dok1 and Dok2 by 
inhibiting ERK, contrary to our findings (Peng et al., 2012). However, the doses of 
LPS used by Peng et al were high doses ranging from 100 ng/ml to 1 g/ml. Their 
claim that ERK was enhanced in the absence of Dok3 may be premised differently as 
their results clearly showed that the differences were not as significantly different as 
compared to wildtype controls upon LPS stimulation. In addition, the mice that were 
utilised in their studies were of 129S1/SvImJ strain, whereas our mice were of the 
C57BL6 strain. The different strains of mice used may yield different experimental 
outcomes under different stimuli as discussed in past literature (Kamath et al., 2003; 
Ripoll et al., 2010). 
 
Last but not least, the lack of major signalling defects by Dok3 deficiency in higher 
doses of TLR4 stimulation prompted us to undertake a MS proteomic approach to 
identify novel interacting partners of Dok3 that would coherently participate in TLR4 




Given that much research was performed to study the role of ABIN1 in endotoxin 
tolerance, it is intriguing to see how Dok3 and ABIN1 participate in activating TLR4 
contribution to sepsis.  Further experiments in establishing the overlapping roles of 
Dok3 and ABIN1 in TLR4 signalling will explain the oddity. Finally the discovery of 
Dok3‟s role in TLR4 signalling could mean that Dok3 represents a novel target for 
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